

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1644PNH

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	4	Apr 09	ZDB will be removed from STN
NEWS	5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS	8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS	9	Jun 03	New e-mail delivery for search results now available
NEWS	10	Jun 10	MEDLINE Reload
NEWS	11	Jun 10	PCTFULL has been reloaded
NEWS	12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS	13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS	14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS	15	Jul 30	NETFIRST to be removed from STN
NEWS	16	Aug 08	CANCERLIT reload
NEWS	17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	18	Aug 08	NTIS has been reloaded and enhanced
NEWS	19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS	21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS	22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	23	Sep 03	JAPIO has been reloaded and enhanced
NEWS	24	Sep 16	Experimental properties added to the REGISTRY file
NEWS	25	Sep 16	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS	26	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	27	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS EXPRESS			February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 19:04:28 ON 07 OCT 2002

=> file medline embase biosis scisearch caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 19:04:43 ON 07 OCT 2002

FILE 'EMBASE' ENTERED AT 19:04:43 ON 07 OCT 2002

COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 19:04:43 ON 07 OCT 2002

COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'SCISEARCH' ENTERED AT 19:04:43 ON 07 OCT 2002

COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'CAPLUS' ENTERED AT 19:04:43 ON 07 OCT 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s "Apo-I"

L1 695 "APO-I"

=> s l1 and conjugate

L2 3 L1 AND CONJUGATE

=> dup reomve l2

ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove

'REOMVE' IS NOT VALID. VALID FILE NAMES ARE 'CAPLUS'

You have entered a file name of duplicates to keep that is not referenced by any of the L#s specified for this DUPLICATE command. The file names of duplicates that can be kept are listed above. Please enter one of these file names.

=> dup remove l2

PROCESSING COMPLETED FOR L2

L3 3 DUP REMOVE L2 (0 DUPLICATES REMOVED)

=> d l3 1-3 cbib abs

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2002 ACS

1989:111335 Document No. 110:111335 Reagents for reactivation by cofactor of an apoenzyme-antigen **conjugate** in an enzyme immunoassay method. Siddiqi, Iqbal; Mangan, Ciaron (Battelle Memorial Institute, Switz.). Eur. Pat. Appl. EP 274343 A1 19880713, 9 pp. DESIGNATED STATES: R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1987-810005 19870106.

AB A homogeneous EIA is described in which an apoenzyme conjugated to an antigen is regenerated by addn. of a cofactor, and regeneration of the holoenzyme is inhibited by complexing the antigen to an antibody. Alk. phosphatase (I), conjugated to a rabbit antibody to human IgG, was completely inhibited by 10-2M 1,10-phenanthroline. The activity was 10-20% restored by addn. of 0.3M Zn2+, as compared to 100% for unconjugated I; thus conjugation altered the kinetics of reactivation, but reactivation was sufficient for use of the **conjugate** in an EIA.

When the **apo-I-antibody conjugate** was incubated with donkey anti-rabbit IgG antiserum, the greater the amt. of antiserum in the assay medium, the less the I activity was rescued by Zn2+. Addn. of competing unlabeled rabbit IgG (analyte) allowed restoration of I activity by Zn2+.

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2002 ACS

1985:518335 Document No. 103:118335 Purification and characterization of cytosolic liver protein facilitating heme transport into apocytochrome b5 from mitochondria. Evidence for identifying the heme transfer protein as belonging to a group of glutathione S-transferases. Senjo, Masanori; Ishibashi, Teruo; Imai, Yoh (Sch. Med., Hokkaido Univ., Sapporo, 060, Japan). J. Biol. Chem., 260(16), 9191-6 (English) 1985. CODEN: JBCHA3. ISSN: 0021-9258.

AB The transport of protoheme from mitochondria to apocytochrome b5 (**apo-I**) was examd. by incubation of fresh rat liver mitochondria with **apo-I** and cytosol. The heme-transfer protein was purified .apprx.133- to 140-fold from rat liver cytosol, with a 43% yield by procedures which included Sephadex G-75 and CM-cellulose column chromatog. The final prepn. was apparently homogeneous by SDS-polyacrylamide gel electrophoresis. Its native form was a dimeric protein with a mol. wt. of 45,000 which consisted of a subunit with a mol. wt. of 23,000. Heme transfer depended on the concn. of mitochondria (donor), **apo-I** (acceptor), and purified transfer protein. Omission of any of these components led to an almost complete loss of the transfer activity. The transport of mitochondrial protoheme was rapid and approx. linear for .ltoreq.1.5 min, after which it became satd. When the functional capacity was tested by the NADH-cytochrome c reductase system, the reconstituted I expressed its complete original catalytic properties, as well as its characteristic absorption spectra for the hemoprotein. Furthermore, the detailed physicochem. and immunol. characterization of the transfer protein indicated that the protein was identical with sol. glutathione S-transferase (II), which **conjugates** glutathione with a variety of electrophilic compds. At least 1 of the II isoenzymes obsd. was II-C2 by immunopptn. with various anti-II isoenzyme antibodies.

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2002 ACS

1981:202859 Document No. 94:202859 Inhibition of kynureninase (L-kynurenine hydrolase, EC 3.7.1.3) by estrone sulfate: an alternative explanation for abnormal results of tryptophan load tests in women receiving estrogenic steroids. Bender, David A.; Wynick, David (Courtauld Inst. Biochem., Middlesex Hosp. Med. Sch., London, W1P 7PN, Engl.). Br. J. Nutr., 45(2), 269-75 (English) 1981. CODEN: BJNUAV. ISSN: 0007-1145.

AB Rat liver kynureninase (EC 3.7.1.3) (I) [9024-78-6], in a partially purified cofactor-free prepn., was uncompetitively inhibited by estrone sulfate [481-97-0] with respect to pyridoxal phosphate and competitively inhibited with respect to kynurenine with a Ki of 82 .mu.M. Addn. of a satg. concn. of pyridoxal phosphate to unfractionated liver homogenates increased I activity .apprx.5-fold, indicating the presence of a relatively large amt. of **apo-I**. It was suggested that the abnormal results of tryptophan load tests in women receiving estrogens may be the result of I inhibition by estrogen **conjugates** and that estrogen-induced vitamin B6 [8059-24-3] deficiency probably does not occur.

=> s l1 and ortholog

L4 0 L1 AND ORTHOLOG

=> s human apolipoprotein AI

L5 300 HUMAN APOLIPOPROTEIN AI

=> s 15 and cynomolgus monkey  
L6 0 L5 AND CYNOMOLGUS MONKEY

=> s 15 and macaca fascicularis  
L7 0 L5 AND MACACA FASCICULARIS

=> s 15 and PEG modified  
L8 0 L5 AND PEG MODIFIED

=> s 15 and polyethylene glycol  
L9 0 L5 AND POLYETHYLENE GLYCOL

=> dup remove 15  
PROCESSING COMPLETED FOR L5  
L10 150 DUP REMOVE L5 (150 DUPLICATES REMOVED)

=> s 110 and conjugate  
L11 1 L10 AND CONJUGATE

=> d 111 cbib abs

L11 ANSWER 1 OF 1 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
92269493 EMBASE Document No.: 1992269493. Rapid screening method for polymorphism of group A apolipoproteins. Harake B.; Caines P.S.M.; Thibert R.J.. Department of Chemistry/Biochemistry, University of Windsor, Windsor, Ont. N9B 3P4, Canada. Journal of Clinical Laboratory Analysis 6/5 (290-296) 1992.  
ISSN: 0887-8013. CODEN: JCANEM. Pub. Country: United States. Language: English. Summary Language: English.  
AB Polymorphism of apolipoproteins AI and AII (apo AI and apo AII) can be easily investigated in plasma by a simple method involving a 30-min incubation of EDTA plasma in the presence of urea, dithiothreitol, and Nonidet P-40 followed by subsequent isoelectric focusing (IEF). The sample (2 .mu.L) was applied to an ultrathin flat acrylamide gel of pH range 4-6, and focused using a Bio-Rad.RTM. Mini IEF Cell for 1.5 h at a maximum of 500 V. Coomassie Blue R-250 was used to visualize the apolipoproteins. To verify the identity of the different apolipoproteins after IEF, the gel was immunofixed directly with anti-3apo AI, or immunoblotted on polyvinylidene difluoride (PVDF) membrane using monospecific antibodies to apo AI and apo AII and an anti-immunoglobulin-alkaline phosphatase **conjugate**. High-density lipoprotein (HDL) was used as a standard for Apo AI variants. Employing these techniques, human plasma apo AI was resolved into one major band (apo AI0, pI 5.54), and four minor bands identified as apo AI+2 (pI 5.75), apo AI+1 (pI 5.66), apo AI-1 (pI 5.45), and apo AI-2 (pI 5.34). Apo AII was resolved into one major isoprotein designated as apo AII0 (pI 4.87), and two minor isoforms apo AII+1 and apo AII-1 which focused at pIs of 5.18 and 4.58, respectively. The results showed that these methods can be used to identify apo AI and AII isoforms without prior ultracentrifugation to isolate the HDL. The entire procedure, including IEF, fixation (chemical or immunofixation), and staining, can be accomplished in 5 h compared to 2 days using previously reported technique. The identification and characterization of **human apolipoprotein AI** and AII isoforms is important in clinical practice, e.g., diagnosis of tangier disease, and may be useful in studying structure- function relationships of these apoproteins.

=> s 110 and copolymer  
L12 0 L10 AND COPOLYMER

=> d his

(FILE 'HOME' ENTERED AT 19:04:28 ON 07 OCT 2002)

FILE 'MEDLINE, EMBASE, BIOSIS, SCISEARCH, CAPLUS' ENTERED AT 19:04:43 ON  
07 OCT 2002

L1 695 S "APO-I"  
L2 3 S L1 AND CONJUGATE  
L3 3 DUP REMOVE L2 (0 DUPLICATES REMOVED)  
L4 0 S L1 AND ORTHOLOG  
L5 300 S HUMAN APOLIPOPROTEIN AI  
L6 0 S L5 AND CYNOMOLGUS MONKEY  
L7 0 S L5 AND MACACA FASCICULARIS  
L8 0 S L5 AND PEG MODIFIED  
L9 0 S L5 AND POLYETHYLENE GLYCOL  
L10 150 DUP REMOVE L5 (150 DUPLICATES REMOVED)  
L11 1 S L10 AND CONJUGATE  
L12 0 S L10 AND COPOLYMER

=> s l1 and macaca fascicularis  
L13 0 L1 AND MACACA FASCICULARIS

=> s polymer  
L14 1510697 POLYMER

=> s l14 and water soluble  
L15 37443 L14 AND WATER SOLUBLE

=> s l15 adn polyethylene glycol  
MISSING OPERATOR L15 ADN  
The search profile that was entered contains terms or  
nested terms that are not separated by a logical operator.

=> s l15 and polyethylene glycol  
L16 2874 L15 AND POLYETHYLENE GLYCOL

=> s l16 and monomethoxy polyethylene glycol  
L17 0 L16 AND MONOMETHOXY POLYETHYLENE GLYCOL

=> s l16 adn dextran  
MISSING OPERATOR L16 ADN  
The search profile that was entered contains terms or  
nested terms that are not separated by a logical operator.

=> s l16 and dextran  
L18 228 L16 AND DEXTRAN

=> s l18 and ApoAI  
L19 0 L18 AND APOAI

=> s l18 and peptide  
L20 35 L18 AND PEPTIDE

=> dup remove l20  
PROCESSING COMPLETED FOR L20  
L21 35 DUP REMOVE L20 (0 DUPLICATES REMOVED)

=> d l21 1-35 cbib abs

L21 ANSWER 1 OF 35 CAPLUS COPYRIGHT 2002 ACS  
2002:185399 Document No. 136:229029 Method for precipitating mono and  
multiple layers of organophosphoric and organophosphonic acids and the  
salts thereof in addition to use thereof. Hofer, Rolf; Pawlak, Michael;  
Textor, Marcus; Schuermann-Mader, Eveline; Ehrat, Markus; Tosatti, Samuele  
(Zeptosens A.-G., Switz.). PCT Int. Appl. WO 2002020873 A2 20020314, 88

pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (German). CODEN: PIXXD2. APPLICATION: WO 2001-EP10077 20010831. PRIORITY: CH 2000-1732 20000905.

AB The invention relates to a method for pptg. mono or multiple layers of organophosphoric acids of general formula (I(A)) Y-B-OPO<sub>3</sub> H<sub>2</sub> (IA) or organophosphonic acids of general formula (I(B)) Y-B-PO<sub>3</sub> H<sub>2</sub> (IB) and the salts thereof, wherein B is an alkyl, alkenyl, alkynyl, aryl, aralkyl, hetaryl or hetaryl alkyl radical and Y is hydrogen or a functional group from the hydroxy, carboxy, amino, optionally low-alkyl- substituted mono or dialkylamino series, thiol, or a neg. acid group from the ester, phosphate, phosphonate, sulfate, sulfonate, maleimide, succinimidyl, epoxy, acrylate series. A biol., biochem. or synthetic indicator element can be coupled to B or Y as addn. or substitution reaction, whereby compds. can also be added imparting on the substrate surface a resistance against protein absorption and/or cell adhesion and in the B chain can be, optionally, composed of one or more ethylene oxide groups rather than one or more CH<sub>2</sub> groups. According to the invention, said pptn. occurs on the surfaces of the substrates of pure or mixed oxides, nitrides or carbides of metals and semi-conductors. The invention is characterized in that the **water-sol.** salts composed of formula (IA) or (IB) are used to treat said surfaces, esp. the surfaces of sensor platforms, implants and medical accessory devices. The invention also relates to the use thereof as part of coated sensor platforms, implants and medical accessory devices in addn. to novel organophosphoric acids and organophosphonic acids themselves. The optionally substituted compds. of general formula (IA) and (IB), wherein the groups B and Y have the above mentioned designations i.e. optionally substituted alkyl, alkenyl, alkynyl, aryl, aralkyl, hetaryl or hetaryl, are equally called organophosphoric acids or phosphonic acids.

L21 ANSWER 2 OF 35 CAPLUS COPYRIGHT 2002 ACS

2002:90103 Document No. 136:149873 IL-17 molecules and uses thereof. Medlock, Eugene; Yeh, Richard; Silbiger, Scott M.; Elliot, Gary S.; Nguyen, Hung Q.; Jing, Shuqian (Amgen, Inc., USA). PCT Int. Appl. WO 2002008285 A2 20020131, 242 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US19861 20010621. PRIORITY: US 2000-PV213125 20000622; US 2001-PV266159 20010202; US 2001-810384 20010316.

AB Novel IL-17 like polypeptides and nucleic acid mols. encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing IL-17 like polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with IL-17 like polypeptides, agonists, or antagonists thereof.

L21 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2002 ACS

2002:10538 Document No. 136:84704 Thymic stromal lymphopoietin receptor molecules and uses thereof. Pandey, Akhilesh; Ozaki, Katsutoshi; Baumann, Heinz; Levin, Steven D.; Farr, Andrew G.; Ziegler, Steven F.; Leonard, Warren J.; Lodish, Harvey F. (Whitehead Institute for Biomedical Research, USA). PCT Int. Appl. WO 2002000723 A2 20020103, 133 pp. DESIGNATED

STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US20730 20010628. PRIORITY: US 2000-PV214658 20000628.

AB The present invention provides Thymic Stromal Lymphopoietin Receptor (TSLPR) polypeptides and nucleic acid mols. encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TSLPR polypeptides. The invention further provides pharmaceutical compns. and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions assocd. with TSLPR polypeptides.

L21 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2002 ACS

2002:409180 Document No. 137:1563 CD20/IgE-receptor like molecules and uses thereof. Welcher, Andrew A.; Calzone, Frank J. (USA). U.S. Pat. Appl. Publ. US 2002064823 A1 20020530, 46 pp., Cont.-in-part of U. S. Ser. No. 723,258. (English). CODEN: USXXCO. APPLICATION: US 2001-821821 20010329. PRIORITY: US 2000-PV193728 20000330; US 2000-723258 20001127.

AB Novel CD20/IgE-receptor like polypeptides and nucleic acid mols. encoding the same. The invention also provides vectors, host cells, agonists and antagonists (including selective binding agents), and methods for producing CD20/IgE-receptor like polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with CD20/IgE-receptor like polypeptides.

L21 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2002 ACS

2002:294172 Document No. 136:324075 IL-17 receptor-like polypeptides, polynucleotides and antibodies for identification of agonists and antagonists and for diagnosis/treatment of immune diseases. Jing, Shuqian (USA). U.S. Pat. Appl. Publ. US 20020045213 A1 20020418, 54 pp., Cont.-in-part of U.S. Ser. No. 724,460. (English). CODEN: USXXCO. APPLICATION: US 2001-809567 20010315. PRIORITY: US 2000-PV189816 20000316; US 2000-724460 20001128.

AB Disclosed are novel IL-17 receptor like polypeptides and nucleic acid mols. encoding the same. The invention also provides vectors, host cells, antibodies, antisense oligonucleotides, agonists and antagonists (including selective binding agents), and methods for producing IL-17 receptor like polypeptides. Also provided are methods for the treatment, diagnosis, amelioration, or prevention of diseases assocd. with IL-17 receptor like polypeptides, e.g. immunol. diseases, autoimmune diseases, inflammation, transplant rejection, allergies, infections, obesity, anorexia, cachexia, neuronal diseases, lung diseases, skin diseases, kidney diseases, bone diseases, vascular diseases, cancer, etc. The invention further provides method for identifying antibody, small mol., protein, **peptide**, lipid, carbohydrate that mimicking or antagonizing the biol. activity of IL-17 receptor-like mol.

L21 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2002 ACS

2002:241284 Document No. 136:261833 Sequence homologs of interleukin 17 and their use in diagnosis and treatment of immunol. diseases, inflammations and infections. Medlock, Eugene; Yeh, Richard; Silbiger, Scott M.; Elliott, Gary S.; Nguyen, Hung Q.; Jing, Shuqian (USA). U.S. Pat. Appl. Publ. US 20020037524 A1 20020328, 91 pp., Cont.-in-part of U.S. Ser. No. 810,384. (English). CODEN: USXXCO. APPLICATION: US 2001-886404 20010621. PRIORITY: US 2000-PV213125 20000622; US 2001-PV266159 20010202; US 2001-810384 20010316.

AB Novel sequence homologs of IL-17 polypeptides (IL-17E) and nucleic acid mols. encoding the same are disclosed. The invention also provides vectors, host cells, antibodies and other selective binding agents, and

methods for producing IL-17 like polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with IL-17 like polypeptides, agonists, or antagonists thereof. Methods of high throughput drug screening for effectors of IL-17 polypeptides are another embodiment of the present invention.

L21 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2002 ACS

2002:271976 Document No. 136:274360 Osteoprotegerin in treatment of osteoporosis and other bone diseases. Boyle, William J.; Lacey, David L.; Calzone, Frank J.; Chang, Ming-Shi (Amgen Inc., USA). U.S. US 6369027 B1 20020409, 117 pp., Cont. of U.S. Ser. No. 577,788. (English). CODEN: USXXAM. APPLICATION: US 1996-706945 19960903. PRIORITY: US 1995-577788 19951222.

AB The present invention discloses a novel secreted polypeptide, osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metab. Also disclosed are rat, mouse and human nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compns. Expression of rat OPG cDNA in transgenic mouse showed increase in bone d., particularly in femurs, pelvic bones and vertebrae. C-terminal truncations of osteoprotegerin are provided that inhibit bone resorption. Specifically, amino acid residues 22-185 which comprise four cysteine-rich domains are required for osteoprotegerin activity. Furthermore, osteoprotegerin monomers may be linked by disulfide linkages and the dimeric form of OPG appears to predominate in transgenic mice, although trimeric forms may also exist. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis.

L21 ANSWER 8 OF 35 CAPLUS COPYRIGHT 2002 ACS

2001:886197 Document No. 136:32779 Novel cysteine-knot growth factor superfamily member: Cloaked-2 protein from human and mouse, their recombinant production and use in therapeutics. Paszty, Christopher J.; Gao, Yongming (Amgen, Inc., USA). PCT Int. Appl. WO 2001092308 A2 20011206, 171 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US17478 20010529. PRIORITY: US 2000-PV208550 20000601; US 2000-PV223542 20000804.

AB The present invention provides protein and cDNA sequences for novel Cloaked-2 proteins from human and mouse, which belong to cysteine-knot growth factor superfamily with conserved cysteine-knot motifs (CxGxC or CxC). The mRNA tissue expression profile of human Cloaked-2 protein is provided. The invention also provides vectors, host cells, selective binding agents, and methods for producing Cloaked-2 polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with Cloaked-2 polypeptides. The invention further provides antibodies specific to Cloaked-2 proteins useful in therapeutics.

L21 ANSWER 9 OF 35 CAPLUS COPYRIGHT 2002 ACS

2001:833368 Document No. 135:370651 Receptor from TNF family. Boyle, William J.; Hsu, Hailing (Amgen Inc., USA). PCT Int. Appl. WO 2001085782 A2 20011115, 124 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF,



CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2.  
APPLICATION: WO 2001-US4568 20010212. PRIORITY: US 2000-PV181800  
20000211.

AB A member of the tumor necrosis factor family and its receptor are described. This member is primarily expressed in B cells and its expression correlates to increases in the no. of B cells and Igs produced. The natural, preferred human ortholog is here called AGP-3R. The protein is a type III transmembrane protein and has an amino terminal extracellular domain, a transmembrane domain, and a carboxy terminal intracellular domain. AGP-3R-related proteins of the invention may be membrane-assocd. or in sol. form, recombinantly produced or isolated after natural prodn. The invention provides for nucleic acids encoding such AGP-3R-related proteins, vectors and host cells expressing the polypeptides, and methods for producing recombinant proteins. Antibodies or fragments thereof that specifically bind the proteins are also provided. AGP-3R agonists and antagonists are useful for modulating B cell response and treating inflammatory, immunol., and autoimmune diseases, e.g. rheumatoid arthritis, graft vs. host disease, lupus erythematosus, and Crohn's disease.

L21 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2002 ACS

2001:747853 Document No. 135:302897 CD20/IgE-receptor like molecules and uses thereof. Welcher, Andrew A.; Calzone, Frank J. (Amgen, Inc., USA). PCT Int. Appl. WO 2001074903 A2 20011011, 145 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US10048 20010329. PRIORITY: US 2000-PV193728 20000330; US 2000-723258 20001127.

AB Novel CD20/IgE-receptor like polypeptides and nucleic acid mols. encoding the same. The invention also provides vectors, host cells, agonists and antagonists (including selective binding agents), and methods for producing CD20/IgE-receptor like polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with CD20/IgE-receptor like polypeptides.

L21 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2002 ACS

2001:713560 Document No. 135:268321 Human and murine fibroblast growth factor receptor-like polypeptides and encoding nucleic acids. Saris, Christiaan M.; Mu, Sharon X.; Xia, Min; Boone, Thomas Charles; Covey, Todd (Amgen, Inc., USA). PCT Int. Appl. WO 2001070977 A2 20010927, 163 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US9073 20010322. PRIORITY: US 2000-PV191379 20000322.

AB The present invention provides fibroblast growth Factor receptor-like (FGFR-L) polypeptides and nucleic acid mols. encoding the same found in cDNA libraries from mouse and human tissues. The murine FIGR-L polypeptide comprises a 1587-bp open reading frame encoding a protein of 529 amino acids and possessing a potential signal **peptide** at its N-terminus. Tissue profiling data for expression of the FIGR-L gene are also provided based on Northern blot anal. and RNase protection assays. The invention also provides selective binding agents, vectors, host cells,

and methods for producing FGFR-L polypeptides. The invention further provides pharmaceutical compns. and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions assocd. with FGFR-L polypeptides.

L21 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2002 ACS

2001:693376 Document No. 135:271903 IL-17 receptor like molecules and uses thereof. Jing, Shuqian; Medlock, Eugene; Yeh, Richard; Silbiger, Scott M.; Elliot, Gary S.; Nguyen, Hung Q. (Amgen Inc., USA). PCT Int. Appl. WO 2001068705 A2 20010920, 239 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US8688 20010316. PRIORITY: US 2000-PV189923 20000316; US 2000-PV204208 20000512; US 2000-723232 20001127; US 2001-PV266159 20010202.

AB Novel IL-17 receptor like polypeptides and nucleic acid mols. encoding the same. The invention also provides vectors, host cells, agonists and antagonists (including selective binding agents), and methods for producing IL-17 receptor like polypeptides. Also provided for are methods for treatment, diagnosis, amelioration, or prevention of diseases assocd. with IL-17 receptor like polypeptides, e.g. immune system dysfunction, inflammation, cancer and infection.

L21 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2002 ACS

2001:661596 Document No. 135:237110 Cloning and characterization of chordin-like-2 protein genes from human and mouse, diagnostic and therapeutic use thereof. Zhang, Ke; Linh, Cam; Nakayama, Naoki (Amgen, Inc., USA). PCT Int. Appl. WO 2001064885 A1 20010907, 167 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US6891 20010302. PRIORITY: US 2000-PV186462 20000302.

AB The invention provides protein and cDNA sequences for novel human and mouse chordin-like-2 protein CHL2, which has sequence similarity to chordin known as the bone morphogenetic protein (BMP) inhibitor. The invention also provides selective binding agents, vectors, host cells, and methods for producing CHL2 polyproteins. The tissue distribution pattern of the mRNA shows that CHL2 is involved in mouse articular chondrocytes, sternum, placenta, uterus, colon, and small intestine. CHL2 directly interacts with BMPs, and its inhibitory activity is demonstrated in CHL2 gene transfected cells, Xenopus embryo, and in transgenic mice. The murine CHL2 gene is mapped to chromosome 7 centromere. The invention further provides pharmaceutical compns. and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions assocd. with CHL2 polyproteins.

L21 ANSWER 14 OF 35 CAPLUS COPYRIGHT 2002 ACS

2001:472523 Document No. 135:66255 Liquid composition of a biodegradable block copolymer for drug delivery system. Seo, Min-hyo; Choi, In-ja (Samyang Corp., S. Korea). PCT Int. Appl. WO 2001045742 A1 20010628, 37 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT,

LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2000-KR1508 20001221. PRIORITY: KR 1999-60349 19991222.

AB The present invention relates to a liq. polymeric compn. capable of forming a physiol. active substance-contg. implant when it is injected into a living body and a method of prepn. The compn. comprises a **water-sol. biocompatible liq. polyethylene glycol** deriv., a biodegradable block copolymer which is insol. in water but sol. in the **water-sol. biocompatible liq. polyethylene glycol** deriv. and a physiol. active substance. Thus, a triblock copolymer was prepd. from lactide-1,4-dioxanone and PEG. Piroxicam 150, the above biodegradable block copolymer 400, diacetyl **polyethylene glycol** 420, and gelatin 30 mg were dissolved in a 50% aq. HOAc soln. and the drug-contg. liq. polymeric compn. was filtered and the org. solvent was removed.

L21 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2002 ACS  
2001:300486 Document No. 134:331616 Sustained release microspheres based on a carrier protein, a **water soluble polymer** and complexing agents. Scott, Terrence L.; Brown, Larry R.; Riske, Frank J.; Blizzard, Charles D.; Rashba-Step, Julia (Epic Therapeutics, Inc., USA). PCT Int. Appl. WO 2001028524 A1 20010426, 71 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US28200 20001012. PRIORITY: US 1999-420361 19991018.

AB A microsphere compn. for sustained release of therapeutic or diagnostic agents comprises (1) a carrier protein, (2) a **water-sol. polymer**, (3) a polyanionic polysaccharide as a first complexing agent, and (4) a divalent metal cation (Ca and Mg) as a second complexing agent. The microspheres have a smooth surface that includes a plurality of channel openings that are < 1000 .ANG. in diam. Various drugs were encapsulated into microspheres. For example, microspheres contg. leuprolide acetate were prepd. using human serum albumin (HSA), **dextran sulfate, polyethylene glycol**, and polyvinylpyrrolidone. The microspheres were composed of approx. 10% leuprolide acetate, 50% human serum albumin, 20% **dextran sulfate** and 20% **polyethylene glycol**/polyvinylpyrrolidone. Similar particles were prepd. which also included zinc sulfate or caprylic acid, both of which retarded the release of protein and **peptide** from the microspheres. Also, rifampicin-contg. HSA microspheres were prepd. with HSA incorporation of 74% and rifampicin incorporation into the particles of > 6.8%. The av. size of the particles was detd. to be 68 nm in diam.

L21 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2002 ACS  
2001:208500 Document No. 134:219363 Method for preparing electrophoresis supporter gel. Hayashizaki, Yoshihide (Riken Corp., Japan). PCT Int. Appl. WO 2001020317 A1 20010322, 30 pp. DESIGNATED STATES: W: CA, JP, US; RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP6247 20000913. PRIORITY: JP 1999-259013 19990913.


AB A method is described for prepg. an electrophoresis supporter (e.g., gel, entangled **polymer**) by cleaning using a weak alk. soln. (e.g.,

carbonate) at least a part of the surface of a supporting member (e.g., capillary column) contg. silicon used for supporting the electrophoresis supporter, and then, rendering the supporting member to carry the supporter. An electrophoresis gel is composed of a polyacrylamide-type **polymer** obtained by polymg. acrylamide or its deriv. (e.g., N,N-dimethylacrylamide, N-(hydroxymethyl)acrylamide) in the presence of two or more than two polar org. solvents (e.g., formamide, methanol). A method for efficiently sepg. nucleic acid (e.g., DNA, RNA) or PNA fragments by electrophoresis using the gel prepd. by the above method is claimed.

L21 ANSWER 17 OF 35 CAPLUS COPYRIGHT 2002 ACS

2001:168055 Document No. 134:208364 Amphipathic compound having dendritic structure. Tsuchida, Eishun; Takeoka, Shinji; Sou, Keitaro; Ohkawa, Haruki (Japan Science and Technology Corporation, Japan). PCT Int. Appl. WO 2001016211 A1 20010308, 60 pp. DESIGNATED STATES: W: US; RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP5702 20000824. PRIORITY: JP 1999-245731 19990831.

GI



AB An amphipathic compd. having a dendritic structure represented by structural formula (I). In the I, R0 is a hydrophilic group (e.g., oligosaccharides); R1 and R2 each independently is a hydrophobic group; and n is an integer of 1 to 4. This amphipathic compd. can take advantage of the intermol. interaction to stably fix a **water-sol. polymer** on the surface and can hold the same while retaining its intact function. Thus, a low generation dendritic compd. was prepd. by using lysine as a spacer, polyethylene oxide as the hydrophilic moiety former, and palmitic acid as the hydrophobic moiety former.

L21 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2002 ACS

2001:468203 Document No. 135:66201 Conjugates targeted to the interleukin-2 receptor. Prakash, Ramesh K.; Clemens, Christopher M. (Watson Laboratories, Inc., USA). U.S. US 6251866 B1 20010626, 22 pp., Cont.-in-part of U.S. Ser. No. 914,042, abandoned. (English). CODEN: USXXAM. APPLICATION: US 1998-128572 19980804. PRIORITY: US 1997-914042 19970805.

AB A compn. for intracellular delivery of a chem. agent into an interleukin-2-receptor-bearing cell, e.g. an activated T cell, includes a chem. agent and at least one copy of an interleukin-2-receptor-binding and endocytosis-inducing ligand coupled to a **water sol. polymer**. The ligand binds to a receptor on the interleukin-2-receptor-bearing cell and elicits endocytosis of the compn. The compn. also preferably includes a spacer for coupling the chem. agent and the ligand to the **polymer**. Chem. agents can include cytotoxins, transforming nucleic acids, gene regulators, labels, antigens, drugs, and the like. A preferred **water sol. polymer** is a polyalkylene oxide, such as **polyethylene glycol** and polyethylene oxide, and activated derivs. thereof. The compn. can further comprise a carrier such as another **water sol. polymer**, liposome, or particulate. Methods of

using these compns. for delivering a chem. agent in vivo or in vitro are also disclosed. A method of detecting a disease, such as T-cell lymphocytic leukemia, T-cell acute lymphoblastic leukemia, peripheral T-cell lymphoma, Hodgkin's disease, or non-Hodgkin's lymphoma, assocd. with elevated levels of sol. IL-2 receptor is also disclosed.

L21 ANSWER 19 OF 35 CAPLUS COPYRIGHT 2002 ACS

2001:891554 Document No. 136:24952 Surfactant-free emulsion compositions manufactured with **water-soluble polymers**.

Nakano, Mitsuru (Nihon B.E.E. K. K., Japan). Jpn. Kokai Tokkyo Koho JP 2001342108 A2 20011211, 8 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 2000-166727 20000602.

AB The compns., useful for cosmetics, foods, and pharmaceuticals, contain **water-sol. polymers** and are manufd. by directing a jet of fluid along a 1st path and redirecting the fluid in a controlled flow along a new path using a structure placed in the 1st path, wherein the directions of the 1st and the new path are designated to cause shear force and cavitation in the fluid. Liq. paraffin 10.0, cetyl 2-ethylhexanoate 10.0, beeswax 2.5, spermaceti 2.5, Me polysiloxane 0.5, stearic acid 0.5, glycerin 10.0, Me p-hydroxybenzoate 0.2, gum arabic 0.5, H2O 63.29, and lecithin 0.01 wt.% were preliminary emulsified with a homogenizer and emulsified with DeBEE (emulsifying app.) to give an emulsion with av. particle size 343 nm.

L21 ANSWER 20 OF 35 CAPLUS COPYRIGHT 2002 ACS

2001:579316 Document No. 135:134281 Reagent for measuring glycosylated protein. Komiyama, Kishisato (Wako Pure Chemical Industries, Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 2001215229 A2 20010810, 7 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 2000-24916 20000202.

AB A method and a reagent are provided for enzymically measuring a particular glycosylated protein (e.g., glycosylated albumin, glycosylated globulin, glycosylated transferrin, glycosylated HDL, glycosylated LDL, glycosylated anti-trypsin) in a biol. sample (e.g., whole blood, blood serum, blood plasma, urine). The particular glycosylated protein is specifically detd. based on the quantity of glycosylated amino acid or/and glycosylated **peptide** produced upon contacting the sample with a proteinase in the presence of a co-existing substance (e.g., antibodies, **water-sol. polymer**) capable of inhibiting the involvement of glycosylated proteins other than the particular glycosylated protein in the reaction with the proteinase. This method is superior to the conventional HPLC method in its versatility and rapidness.

L21 ANSWER 21 OF 35 CAPLUS COPYRIGHT 2002 ACS

2001:729702 Document No. 135:278032 **Polymer**-based solid oral dosage forms with sustained drug release and high mechanical stability. Kolter, Karl; Schoenherr, Michael; Ascherl, Hermann (BASF A.-G., Germany). Eur. Pat. Appl. EP 1138321 A2 20011004, 14 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO. (German). CODEN: EPXXDW. APPLICATION: EP 2001-105547 20010306. PRIORITY: DE 2000-10015479 20000329.

AB Solid oral dosage forms with sustained release characteristics comprise a drug, a mixt. of poly(vinyl acetate) and PVP, **water-sol. polymers**, and /or low- or high-mol. wt. lipophilic additives. Thus, tablets were prepd. from caffeine 160, Kollidon SR 160, Kollidon VA64 80 and Mg stearate 1.8 mg. The friability of tablets was <0.01% and the breaking strength was >325N.

L21 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2002 ACS

2001:923219 Document No. 136:42852 Preparation of oral sustained-release solid drug dosage forms. Kolter, Karl; Flick, Dieter; Ascherl, Hermann (BASF A.-G., Germany). Ger. Offen. DE 10029201 A1 20011220, 14 pp. (German). CODEN: GWXXBX. APPLICATION: DE 2000-10029201 20000619.

AB Solid oral dosage forms with sustained release properties, contain at

least 1 drug, a preformulated mixt. from poly(vinyl acetate) and polyvinylpyrrolidone, optionally **water-sol.** **polymers** or lipophilic additives as well as the usual excipients. Granules obtained from the above mixt. are tabletted. Thus, a compn. contg. 400 g Kollidone SR/paracetamol mixt. (1:1) was granulated and the granules were mixed with 0.5% Mg stearate and compressed to give tablets.

L21 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2002 ACS

2000:116860 Document No. 132:171073 Conjugates targeted to target receptors and/or interleukin-2 receptors. Prakash, Ramesh K.; Clemens, Christopher M. (Watson Laboratories, Inc.-Utah, USA). PCT Int. Appl. WO 2000007543 A2 20000217, 67 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-US17648 19990804. PRIORITY: US 1998-128572 19980804.

AB A compn. for intracellular delivery of a chem. agent into a target receptor and/or interleukin-2-receptor-bearing cell, e.g. an activated T cell and cancer cell, includes a chem. agent, at least one copy of target-receptor binding and/or an interleukin-2-receptor-binding and endocytosis-inducing ligand coupled to a **water sol.** **polymer.** The ligand binds to a target receptor and/or IL-2 receptor on the target receptor and/or IL-2-receptor-bearing cell and elicits endocytosis of the compn. The compn. also optionally includes a biodegradable spacer for coupling the chem. agent and the ligand to the **polymer.** Chem. agents can include cytotoxins, transforming nucleic acids, gene regulators, labels, antigens, drugs, and the like. A preferred **water sol. polymer** is polyalkylene oxide, such as **polyethylene glycol** and polyethylene oxide, and activated derivs. thereof. The compn. can further comprise a carrier such as another **water sol. polymer**, liposome, or particulate. Methods of using these compns. for delivering a chem. agent in vivo or in vitro are also disclosed. A method of detecting a disease, such as cancer, T-cell lymphocytic leukemia, T-cell acute lymphoblastic leukemia, peripheral T-cell lymphoma, Hodgkin's disease, and non-Hodgkin's lymphoma, assocd. with elevated levels of sol. target receptor and/or IL-2 receptor is also disclosed.

L21 ANSWER 24 OF 35 CAPLUS COPYRIGHT 2002 ACS

2000:139183 Document No. 132:177439 Method for production of physiologically active **peptides.** Hirata, Akira; Murakami, Yoshihiko (Kobe Steel, Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 2000063399 A2 20000229, 6 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 1998-236055 19980821.

AB The title method comprises (1) adding the protease and the protein to a 2-phase **water-sol. polymer** system to hydrolyze the protein; (2) removing the physiol. active **peptide** (i.e., the product) from one phase of the 2-phase **water-sol. polymer** system. The 2-phase **polymer** system comprises **polyethylene glycol** and **dextran.** The enzymic hydrolysis of the protein is done in the **polyethylene glycol** rich phase, and the product is removed from the **dextran** rich phase. The title method is highly efficient.

L21 ANSWER 25 OF 35 SCISEARCH COPYRIGHT 2002 ISI (R)

2000:421268 The Genuine Article (R) Number: 319KX. The size of membrane pores: The effect of non-electrolytes on the conductance of gramicidin. Coates G M P (Reprint); Alder G M; Smart O S; Bashford C L. UNIV BIRMINGHAM, SCH BIOSCI, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND (Reprint);

ST GEORGE HOSP, SCH MED, DEPT BIOCHEM & IMMUNOL, LONDON SW17 0RE, ENGLAND.  
ACTA PHYSICA POLONICA B (MAY 2000) Vol. 31, No. 5, pp. 1097-1107.  
Publisher: ACTA PHYSICA POLONICA B, JAGELLONIAN UNIV, INST PHYSICS.  
REYMONTA 4, 30-059 KRAKOW, POLAND. ISSN: 0587-4254. Pub. country: ENGLAND.  
Language: English.

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

- AB The effects of neutral **polymers** on ion channel conductance have been used in the past to estimate channel radius. We have measured the effect of **Polyethylene-glycol** and **dextrans** on gramicidin-D, a **peptide** ion channel. The availability of high resolution structures of gramicidin-ii allows us to make a direct comparison between the characteristic radius obtained by these experiments and the radius of the channel obtained from the NMR structure. The effects of PEG on gramicidin are significantly different from those observed on other, wider channels, and the experiment suggests that the operational size of the gramicidin channel exceeds that seen in the NMR and crystal structures. Our data using non-dehydrating **polymers** such as **dextrans**, provide estimates of gramicidin channel size smaller than those obtained with PEGs and closer to those predicted by the NMR and crystal structures.

L21 ANSWER 26 OF 35 CAPLUS COPYRIGHT 2002 ACS

1999:133618 Document No. 130:187175 Conjugates targeted to the interleukin-2 receptor. Prakash, Ramesh K. (Theratech, Inc., USA). PCT Int. Appl. WO 9907324 A2 19990218, 53 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG.  
(English). CODEN: PIXXD2. APPLICATION: WO 1998-US16290 19980805.  
PRIORITY: US 1997-914042 19970805.

- AB A compn. for intracellular delivery of a chem. agent into an interleukin-2-receptor-bearing cell, e.g. an activated T cell, includes a chem. agent and at least two copies of an interleukin-2-receptor-binding and endocytosis-inducing ligand coupled to a **water sol . polymer**. The ligand binds to a receptor on the interleukin-2-receptor-bearing cell and elicits endocytosis of the compn. The compn. also optionally includes a spacer for coupling the chem. agent and the ligand to the **polymer**. Chem. agents can include cytotoxins, transforming nucleic acids, gene regulators, labels, antigens, drugs, and the like. A preferred **water sol . polymer** is polyalkylene oxide, such as **polyethylene glycol** and polyethylene oxide, and activated derivs. thereof. The compn. can further comprise a carrier such as another **water sol . polymer**, liposome, or particulate. Methods of using these compns. for delivering a chem. agent in vivo or in vitro are also disclosed.

L21 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2002 ACS

1999:751514 Document No. 131:356114 Temperature-responsive biodegradable **polymers** providing novel drug delivery systems. Yui, Nobuhiko (Foundation for Scientific Technology Promotion, Japan). Jpn. Kokai Tokkyo Koho JP 11322941 A2 19991126 Heisei, 7 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 1998-127979 19980511.

- AB The **polymers**, which are degraded in cells, tissues, or organs by enzymes and temp. increase and are useful as drug carriers, comprise (a) 3-dimensional net work structure of **water-sol . biodegradable polymers** or **polymers** having biodegradable site and (b) temp.-responsive **polymers** grafted on (a). Three N-isopropylacrylamide-N,N-dimethylacrylamide copolymers having amino group at one end (prepn. given, Mn 2600, 4200, or 8800) were treated

with methacryl chloride to give copolymers having methacryl group at the other terminal. A compn. contg. each copolymer, **dextran** methacrylate, ammonium persulfate, and DMSO was irradiated with UV at room temp. for 4 h to give a hydrogel, which was soaked in H<sub>2</sub>O at room temp. for 10 days. Transmittance of the swollen hydrogel in a phosphate buffer was decreased with increase in the temp. for all 3 hydrogels. Degradn. of the swollen gel with dextranase was promoted with increase in the temp. for the hydrogel having grafted chain with Mn 4200 or 8800.

L21 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2002 ACS

1999:746965 Document No. 131:342078 Polyrotaxane supramolecular materials for implants. Yui, Nobuhiko; Ohtani, Akira (Foundation for Scientific Technology Promotion, Japan). Jpn. Kokai Tokkyo Koho JP 11319069 A2 19991124 Heisei, 5 pp. (Japanese). CODEN: JKXXAF. APPLICATION: JP 1998-127978 19980511.

AB The materials comprise cyclic mols. threaded with biodegradable or hydrolyzable groups-terminated **water-sol.** linear macromols., where the cyclic mols. are not eliminated unless the terminal groups are decompd. **Polyethylene glycol** was esterified with succinic anhydride, imidized with N-hydroxysuccinimide, amidated with ethylenediamine, treated with .alpha.-cyclodextrin, and the resulting pseudopolyrotaxane was amidated with Z-Phe-OSu (Su = succinimido) to give a polyrotaxane having degradn. point 298.0.degree..

L21 ANSWER 29 OF 35 SCISEARCH COPYRIGHT 2002 ISI (R)

1999:716175 The Genuine Article (R) Number: 236EY. Bioconjugation in pharmaceutical chemistry. Veronese F M (Reprint); Morpurgo M. UNIV PADUA, DEPT PHARMACEUT SCI, VIA F MARZOLO 5, I-35131 PADUA, ITALY (Reprint). FARMACO (30 AUG 1999) Vol. 54, No. 8, pp. 497-516. Publisher: ELSEVIER SCIENCE SA. PO BOX 564, 1001 LAUSANNE, SWITZERLAND. ISSN: 0014-827X. Pub. country: ITALY. Language: English.

\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

AB **Polymer** conjugation is of increasing interest in pharmaceutical chemistry for delivering drugs of simple structure or complex compounds such **peptides**, enzymes and oligonucleotides. For long time drugs, mainly with antitumoral activity, have been coupled to natural or synthetic **polymers** with the purpose of increasing their blood permanence time, taking advantage of the increased mass that reduces kidney ultrafiltration. However only recently complex constructs were devised that exploit the 'enhanced permeability and retention' (EPR) effect for an efficient tumor targeting, the high molecular weight for adsorption or receptor mediated endocytosis and finally a lysosomotropic targeting, taking advantage of acid labile bonds or cathepsin susceptible polypeptide spacers between **polymer** and drug. New original, very active conjugates of this type, as those based on poly(hydroxyacrylate) **polymers**, are already in advanced state of development. Labile oligonucleotides, including antisense drugs, were also successfully coupled to **polymers** in view of an increased cell penetration and stabilization towards nucleases. However, the most active research activity resides in the field of polypeptides and proteins delivery, mainly for the two following reasons: first of all because a great number of therapeutically interesting compounds are now being produced by genetic engineering in large quantity and, secondly, because these products are difficult to administer to patients for several inherent drawbacks. Proteins are in fact easily digested by many endo- and exo-peptidases present in blood or in other body districts; most of them are immunogenic to some extent and, finally, they are rapidly excreted by kidney ultrafiltration. Covalent **polymer** conjugation at protein surface was demonstrated to reduce or eliminate these problems, since the bound **polymer** behaves like a shield hindering the approach of proteolytic enzymes, antibodies, or antigen processing cell. Furthermore, the increase of the molecular weight of the conjugate allows to overcome the kidney elimination threshold. Many successful results were already



obtained in **peptides** and proteins, conjugated mainly to **water soluble** or amphiphilic **polymers** like poly(ethylene glycol) (PEG), **dextrans**, or styrene-maleic acid anhydride. Among the most successful are the conjugates of asparaginase, interleukin-2 or -6 and neocarcinostatin, to remind some antitumor agents, adenosine deaminase employed in a genetic disease treatment, superoxide dismutase as scavenger of toxic radicals, hemoglobin as oxygen carrier and urokinase and streptokinase as proteins with antithrombotic activity. In pharmaceutical chemistry the conjugation with **polymers** is also of great importance for synthetic applications since many enzymes without loss of catalytic activity become soluble in organic solvents where many drug precursors are. The various and often difficult chemical problems encountered in conjugation of so many different products prompted the development of many synthetic procedures, all characterized by high specificity and mild condition of reaction, now known as 'bioconjugation chemistry'. Bioconjugation developed also the design of new tailor-made **polymers** with the wanted molecular weight, shape, structure and with the functional groups needed for coupling at the wanted positions in the chain. (C) 1999 Elsevier Science S.A. All rights reserved.

L21 ANSWER 30 OF 35 MEDLINE

1999259607 Document Number: 99259607. PubMed ID: 10327623. Aqueous two-phase systems containing self-associating block copolymers. Partitioning of hydrophilic and hydrophobic biomolecules. Svensson M; Berggren K; Veide A; Tjerneld F. (Department of Physical Chemistry 1, Lund University, Sweden. ) JOURNAL OF CHROMATOGRAPHY. A, (1999 Apr 16) 839 (1-2) 71-83. Journal code: 9318488. Pub. country: Netherlands. Language: English.

AB A series of proteins and one membrane-bound **peptide** have been partitioned in aqueous two-phase systems consisting of micelle-forming block copolymers from the family of Pluronic block copolymers as one **polymer** component and **dextran** T500 as the other component. The Pluronic molecule is a triblock copolymer of the type PEO-PPO-PEO, where PEO and PPO are poly(ethylene oxide) and poly(propylene oxide), respectively. Two different Pluronic copolymers were used, P105 and F68, and the phase diagrams were determined at 30 degrees C for these **polymer** systems. Since the temperature is an important parameter in Pluronic systems (the block copolymers form micellar-like aggregates at higher temperatures) the partitioning experiments were performed at 5 and 30 degrees C, to explore the effect of temperature-triggered micellization on the partitioning behaviour. The temperatures correspond to the unimeric (single Pluronic chain) and the micellar states of the P105 **polymer** at the concentrations used. The degree of micellization in the F68 system was lower than that in the P105 system, as revealed by the phase behaviour. A membrane-bound **peptide**, gramicidin D, and five different proteins were partitioned in the above systems. The proteins were lysozyme, bovine serum albumin, cytochrome c, bacteriorhodopsin and the engineered B domain of staphylococcal protein A, named Z. The Z domain was modified with tryptophan-rich **peptide** chains in the C-terminal end. It was found that effects of salt dominated over the temperature effect for the **water-soluble** proteins lysozyme, bovine serum albumin and cytochrome c. A strong temperature effect was observed in the partitioning of the integral membrane protein bacteriorhodopsin, where partitioning towards the more hydrophobic Pluronic phase was higher at 30 degrees C than at 5 degrees C. The membrane-bound **peptide** gramicidin D partitioned exclusively to the Pluronic phase at both temperatures. The following trends were observed in the partitioning of the Z protein. (i) At the higher temperature, insertion of tryptophan-rich **peptides** increased the partitioning to the Pluronic phase. (ii) At the lower temperature, lower values of K were observed for ZT2 than for ZT1.

L21 ANSWER 31 OF 35 CAPLUS COPYRIGHT 2002 ACS

1998:761809 Document No. 130:17218 Targeted delivery to T lymphocytes.  
Prakash, Ramesh K.; Kumar, Vijay (Theratech, Inc., USA). PCT Int. Appl.  
WO 9851336 A1 19981119, 46 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ,  
BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH,  
GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,  
TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR,  
GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG.  
(English). CODEN: PIXXD2. APPLICATION: WO 1998-US9057 19980504.  
PRIORITY: US 1997-857009 19970515.

AB A compn. for intracellular delivery of a chem. agent into a T cell  
comprises a receptor-binding and endocytosis-inducing ligand and a chem.  
agent coupled to a **water sol. polymer**. The  
ligand binds to a receptor on T lymphocytes and elicits endocytosis of the  
compn. The compn. also includes a spacer for coupling the chem. agent and  
the ligand to the **polymer**. Chem. agents can include cytotoxins,  
transforming nucleic acids, gene regulators, labels, antigens, drugs, and  
the like. A preferred **water sol. polymer** is  
polyethyleneglycol and activated derivs. thereof. The compn. can further  
comprise a carrier such as a **water sol.**  
**polymer**, liposome, or particulate. Methods of using these compns.  
for delivering a chem. agent in vivo or in vitro are also disclosed.

L21 ANSWER 32 OF 35 CAPLUS COPYRIGHT 2002 ACS  
1996:676099 Document No. 125:309046 Drug release systems containing  
**water-soluble polymer** domain and biodegradable  
hydrogel as matrix. Yui, Nobuhiko (Shingijutsu Kaihatsu Jigyodan, Japan).  
Jpn. Kokai Tokkyo Koho JP 08231435 A2 19960910 Heisei, 5 pp.  
(Japanese). CODEN: JKXXAF. APPLICATION: JP 1995-38427 19950227.

AB Stimulation-responsive drug release systems comprise **water-**  
**sol. polymer** domain (e.g. **polyethylene**  
**glycol**) and biodegradable hydrogel (e.g. **dextran**) as  
matrix. Active ingredients such as insulin showed selective distribution  
in the **polyethylene glycol-dextran** diphasic.  
Active ingredients (e.g. insulin) as well as the **polymer** domain  
are released in response to biodegradn. of biodegradable hydrogel from the  
surface.

L21 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2002 ACS  
1995:319762 Document No. 122:89553 PEG hydrazone and PEG oxime linkage  
forming reagents and protein derivatives.. Wright, David E. (Ortho  
Pharmaceutical Corp., USA). Eur. Pat. Appl. EP 605963 A2 19940713, 47 pp.  
DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU,  
MC, NL, PT, SE. (English). CODEN: EPXXDW. APPLICATION: EP 1993-309825  
19931207. PRIORITY: US 1992-987739 19921209; US 1993-45052 19930407; US  
1993-157343 19931123.

AB Compds. for modifying polypeptides with PEG or other **water-**  
**sol. org. polymers** are described. The **water-**  
**sol. polymer** reagents include hydrazine, hydrazine  
carboxylate, semicarbazole, thiosemicarbazide, carbonic acid dihydrazide,  
carbazine, thiocarbazine, and arylhydrazide derivs. as well as oxylamine  
derivs. of **water-sol. org. polymers**, such as  
**polyethylene glycol**, polypropylene glycol,  
polyoxyethylated polyol, heparin, heparin fragments, **dextran**  
polysaccharides, polyamino acids, and polyvinyl alc. Kits for modifying  
polypeptides with the above **water-sol. polymer**  
reagents are also provided. Thus, erythropoietin was modified by oxidn.  
and treatment with monomethoxypolyoxyethylene semicarbazide and the  
product was sepd. by chromatog. The antigenicity and the effect on  
hematocrit levels of the above derivs. were demonstrated.

L21 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2002 ACS

1992:190638 Document No. 116:190638 Separation of mixtures by two-phase systems. Hsu, James T. (Lehigh University, USA). U.S. US 5078886 A 19920107, 10 pp. Cont.-in-part of U.S. 4,980,065. (English). CODEN: USXXAM. APPLICATION: US 1990-591832 19901002. PRIORITY: US 1989-423333 19891018.

AB An org. 2-phase system is useful for the sepn. and purifn. of chems., biochems., and optical isomers. The 2-phase system can be formed with **water-sol. polymers** as 1 phase, and a chiral compd. as the other phase together with a water-miscible org. solvent and/or water. A L-lysine/PEG 8000/H2O system was prepd. and used to sep. D- and L-phenylalanine. L-Phenylalanine gave a lower partition coeff. than D-phenylalanine and was therefore enriched in the L-lysine (lower) phase.

L21 ANSWER 35 OF 35 CAPLUS COPYRIGHT 2002 ACS

1991:488820 Document No. 115:88820 Two-phase system comprising chiral compound and **water soluble polymer** for mixture separation. Hsu, James T. (Lehigh University, USA). U.S. US 4980065 A 19901225, 8 pp. (English). CODEN: USXXAM. APPLICATION: US 1989-423333 19891018.

AB An aq. two-phase system consisting of (1) a chiral compd., (2) a **water sol. polymer**, and (3) water is prepd. for sepg. optical isomer or stereoisomer of (in)org. compds. or biomaterial, e.g. protein, **peptide**, cells and cell particles. The chiral compd. is a D- or L-.alpha.-amino acid or monosaccharide, or disaccharide or chiral salt, or chiral water miscible solvent or chiral acid or chiral base. The **water sol. polymer** is a polypropylene glycol (mol. wt. 300-50,000), poly(vinylpyrrolidone), poly(vinylalc.), **dextran**, and sodium **dextran** sulfate. Thus, 28.57% wt./wt. L-lysine, 10.71% wt./wt. **polyethylene glycol** 8000, and 60.72% wt./wt. water were mixed to form a two-phase system for the sepn. of D- and L-phenylalanine, .beta.-lactoglobulins A and B, and D- and L-tryptophan with D-phenylalanine, .beta.-lactoglobulin A, and D-tryptophan in favor in upper phase. The invention provides an improved process for affinity partitioning and for partition affinity ligand assay. Method studies counter-current distribution, cross-current extn., or counter-current extn. are also included in the process for anal., preparative, and large scale com. sepn. using the two-phase system.

=> s dextran modified Apo-AI

L22 0 DEXTRAN MODIFIED APO-AI

=> s modified Apo A I

L23 12 MODIFIED APO A I

=> dup remove L23

PROCESSING COMPLETED FOR L23

L24 4 DUP REMOVE L23 (8 DUPLICATES REMOVED)

=> d L24 1-4 cbib abs

L24 ANSWER 1 OF 4 MEDLINE

DUPLICATE 1

97382910 Document Number: 97382910. PubMed ID: 9240901. Optimized automated apolipoprotein A-I assays as markers for coronary artery disease. Levinson S S; Hobbs G A. (Department of Veterans Affairs Medical Center, and the Department of Pathology, University of Louisville, KY 40206, USA. ) ARCHIVES OF PATHOLOGY AND LABORATORY MEDICINE, (1997 Jul) 121 (7) 678-84. Journal code: 7607091. ISSN: 0003-9985. Pub. country: United States. Language: English.

AB BACKGROUND: Studies are divided as to whether or not apolipoprotein A-I (apo A-I) is a better marker for coronary artery disease (CAD) than

high-density lipoprotein cholesterol. We hypothesized that the detergent Tween 20, which is thought to expose antigenic sites in apo A-I, would improve automated kit apo A-I assays as a diagnostic marker for CAD. METHODS: Apolipoprotein A-I was assayed by two standard automated methods and by the same methods after serum samples and reagents had been treated with Tween 20. Serum samples were obtained from 226 consecutive male patients, age 40-70 years, presenting for angiography, except for defined exclusion characteristics. Patients were categorized into two groups on the basis of stenosis: (1) normal, all vessels <20% stenosis, n = 79, and (2) CAD, at least one vessel >70% stenosis, n = 147. Diagnostic accuracy was assessed by receiver operator characteristic stenosis curves and forward stepwise logistic regression, where adjustment was made for significant possible confounding characteristics and drugs. RESULTS: The optimal concentration of Tween 20 was found to be 0.5%. Receiver operator characteristic curves showed a greater area for apo A-I with Tween (area = 0.63 to 0.64) as compared to apo A-I without Tween (area = 0.60 to 0.62). Logistic regression indicated that apo A-I with Tween was a significantly better marker than high-density lipoprotein cholesterol. Receiver operator characteristic curves indicated that the ratio of **modified apo A-I** to apo B gave a significant improvement in area over the ratio of high-density to low-density lipoprotein cholesterol. CONCLUSIONS: Addition of Tween 20 to apo A-I assays improved diagnostic discrimination for CAD. The **modified apo A-I** assays were better markers than high-density lipoprotein cholesterol, and the ratio of apolipoproteins was significantly better markers than lipoprotein lipids. These findings may explain the discrepancies between studies comparing high-density lipoprotein cholesterol and apo A-I as markers for CAD. Our data suggest that a multicenter effort toward optimizing and clinically validating apo A-I test reagents may be worthwhile.

- L24 ANSWER 2 OF 4 MEDLINE DUPLICATE 2  
 96206557 Document Number: 96206557. PubMed ID: 8621158. Binding of apolipoprotein A-I and acetaldehyde-modified apolipoprotein A-I to liver extracellular matrix. Paradis V; Mathurin P; Ratziu V; Poynard T; Bedossa P. (Service d'Anatomie Pathologique, Hopital de Bicetre, Le Kremlin-Bicetre, Paris, France.) HEPATOLOGY, (1996 May) 23 (5) 1232-8. Journal code: 8302946. ISSN: 0270-9139. Pub. country: United States. Language: English.
- AB Apolipoprotein A-I (Apo A-I), a protein produced mainly by hepatocytes, is decreased in the sera of alcoholic patients with liver fibrosis and cirrhosis. To explain this decrease, we investigated possible interactions between liver extracellular matrix (ECM) and Apo A-I. Using a solid-phase binding assay, we evaluated the binding of Apo A-I to the different liver matrix components. Apo A-I bound significantly to fibronectin (FN) (optical density [OD] = 1.11 +/- .26, P = .01) and collagen (C) I (OD = 0.91 +/- 0.22, P = .02) in comparison with bovine serum albumin (BSA) (OD = 0.26 +/- 0.16). Binding of Apo A-I to fibronectin was concentration dependent and saturable. Apo A-I bound also to ECM in vivo because Apo A-I was detected by immunofluorescence on fibrous septa in liver biopsy specimens of alcoholic patients. Because a negative correlation between Apo A-I and liver fibrosis is amplified in alcoholic patients, we investigated whether the in vitro formation of Apo A-I/acetaldehyde complex (adducts) increased the binding of Apo A-I to the ECM. We showed that the amount of Apo A-I that bound to FN was significantly higher with acetaldehyde-**modified Apo A-I** (OD = 2.18 +/- 0.19, P = .01) than with native Apo A-I. This increase was probably related to the formation and binding of Apo A-I dimers, because immunoblot of in vitro acetaldehyde-**modified Apo A-I** showed the formation of dimeric Apo A-I. In conclusion, FN binds both native and acetaldehyde-**modified Apo A-I**. Because FN is deposited early and in excess during liver fibrosis, a storage mechanism of Apo A-I on newly

deposited fibronectin would explain, in part, the decrease observed in alcoholic patients with liver fibrosis.

L24 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2002 ACS

1995:541414 Document No. 122:299055 Cholesteryl ester transfer protein inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments. Kushwaha, Rampratap S.; McGill, Henry C., Jr.; Kanda, Patrick (Southwest Foundation for Biomedical Research, USA). PCT Int. Appl. WO 9504755 A1 19950216, 47 pp. DESIGNATED STATES: W: AU, CA, JP, KR; RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (English). CODEN: PIXXD2. APPLICATION: WO 1994-US8624 19940802. PRIORITY: US 1993-102160 19930804.

AB A polypeptide and analogs thereof inhibit cholesteryl ester transfer protein (CETP). An anti-atherosclerosis compn. comprises an anti-atherosclerosis effective amt. of the polypeptide and a pharmaceutically acceptable carrier. An anti-atherosclerosis kit comprises in sep. sterile containers at least one unit of the compn. contg. the polypeptide, one syringe, and one needle. An antibody has specificity for the polypeptide of the invention, the baboon CETP 4-kDa polypeptide inhibitor, the 1-36 amino acid N-terminal fragment of apoC-I, **modified apo A-I** (mol. wt. 31 kDa), or modified apoE (mol. wt. 41 kDa). A method of preventing atherosclerosis in a mammal being predisposed to that condition comprises administering to the mammal a prophylactically effective amt. of the polypeptide of the invention, and a method of treating a mammal afflicted with atherosclerosis comprises the administration of a therapeutically effective amt. of the polypeptide. The peptides consist of the N-terminal 36 residues of baboon apoC-I, a synthetic peptide adding an N-terminal Ala-Pro dipeptide, the human 38-residue analog, and active fragments and substituted analogs.

L24 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2002 ACS

1993:552092 Document No. 119:152092 Cholesteryl ester transfer protein (CETP) inhibitor polypeptide, antibodies against the synthetic polypeptide, and prophylactic and therapeutic anti-atherosclerosis treatments. Kushwaha, Rampratap; Born, Kathleen; McGill, Henry C., Jr.; Kanda, Patrick; Dunham, Raymond G. (Southwest Foundation for Biomedical Research, USA). PCT Int. Appl. WO 9311782 A1 19930624, 46 pp. DESIGNATED STATES: RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (English). CODEN: PIXXD2. APPLICATION: WO 1992-US10846 19921215. PRIORITY: US 1991-811049 19911219.

AB A polypeptide and analogs thereof inhibit CETP. Also disclosed are methods using the polypeptide of the invention for prevention and treatment of atherosclerosis, an anti-atherosclerosis compn., and an anti-atherosclerosis kit. An antibody is disclosed which has specificity for the polypeptide of the invention, the baboon CETP 4 kDa polypeptide inhibitor, the 1-36 apo C-I amino-terminal fragment, **modified apo A-I** (31 kDa mol. wt.), or modified apo E (41 kDa mol. wt.). Sequences of polypeptide inhibitors are included. Detection of the CETP inhibitor peptide in the plasma of baboons with a high HDL1 phenotype is described, as is CETP inhibition by various peptide fragments.

=> s fusion protein

L25 133094 FUSION PROTEIN

=> s 125 chimeric

MISSING OPERATOR L25 CHIMERIC

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s 125 and chimeric

L26 17559 L25 AND CHIMERIC

=> s 126 and IgG

L27 723 L26 AND IGG

=> s 127 and Apo A I

L28 0 L27 AND APO A I

=> s 127 and human Apo-A-I

3 FILES SEARCHED...

L29 0 L27 AND HUMAN APO-A-I

=> s 127 and apolipoprotein AI

L30 0 L27 AND APOLIPOPROTEIN AI

=> s (dayer j?/au or burger d?/au or kohno t?/au or edwards c?/au)

L31 14667 (DAYER J?/AU OR BURGER D?/AU OR KOHNO T?/AU OR EDWARDS C?/AU)

=> s 131 and ApoAI

L32 1 L31 AND APOAI

=> d 132 cbib abs

L32 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS

2001:798252 Document No. 135:362518 Apo-AI/AII peptide derivatives for hypocholesteremic and antiviral therapy. **Kohno, Tadahiko** (Amgen Inc., USA). PCT Int. Appl. WO 2001081376 A2 20011101, 49 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US13068 20010423. PRIORITY: US 2000-PV198920 20000421.

AB The present invention concerns therapeutic agents that mimic the activity of Apo-AI amphipathic helix peptide. In accordance with the present invention, the compds. of the invention comprise: (a) a Apo-AI amphipathic helix peptide or Apo-AI amphipathic helix peptide-mimetic domain, preferably the amino acid sequence of SEQ ID NO:7, or sequences derived therefrom by phage display, RNA-peptide screening, or the other techniques mentioned above; and (b) a vehicle, such as a polymer (e.g., PEG or dextran) or an Fc domain, which is preferred; wherein the vehicle, preferably an Fc domain, is covalently attached to the Apo-AI amphipathic helix peptide or Apo-AI amphipathic helix peptide-mimetic domain. The vehicle and the Apo-AI amphipathic helix peptide or Apo-AI amphipathic helix peptide-mimetic domain may be linked through the N- or C-terminus of the Apo-AI amphipathic helix peptide or Apo-AI amphipathic helix peptide-mimetic domain, as described further below. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain. Preferred Apo-AI amphipathic helix peptide or Apo-AI amphipathic helix peptide-mimetic domains comprise the amino acid sequences described in Table 1. Other Apo-AI amphipathic helix peptide or Apo-AI amphipathic helix peptide-mimetic domains can be generated by phage display, RNA-peptide screening and the other techniques mentioned herein.

=> s 131 and human Apo-A-I

3 FILES SEARCHED...

L33 0 L31 AND HUMAN APO-A-I

=> s 131 and IgG fusion

L34 0 L31 AND IGG FUSION

=> s 11 and lipoprotein  
L35 142 L1 AND LIPOPROTEIN

=> dup remove 135  
PROCESSING COMPLETED FOR L35  
L36 124 DUP REMOVE L35 (18 DUPLICATES REMOVED)

=> s 136 and modified  
L37 1 L36 AND MODIFIED

=> d 137 cbib abs

L37 ANSWER 1 OF 1 SCISEARCH COPYRIGHT 2002 ISI (R)  
93:736313 The Genuine Article (R) Number: MM035. ENDOCYTOSIS AND DEGRADATION  
OF BOVINE APO-LACTOFERRIN AND HOLO-LACTOFERRIN BY ISOLATED RAT HEPATOCYTES  
ARE MEDIATED BY RECYCLING CALCIUM-DEPENDENT BINDING-SITES. MCABEE D D  
(Reprint); NOWATZKE W; OEHLER C; SITARAM M; SBASCHNIG E; OPFERMAN J T;  
CARR J; ESBENSEN K. UNIV NOTRE DAME, DEPT BIOL SCI, NOTRE DAME, IN, 46556  
(Reprint). BIOCHEMISTRY (14 DEC 1993) Vol. 32, No. 49, pp. 13749-13760.  
ISSN: 0006-2960. Pub. country: USA. Language: ENGLISH.  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

AB We characterized endocytosis of iron-saturated(holo) and iron-depleted  
(apo) I-125-labeled bovine lactoferrin (Lf) by  
isolated rat hepatocytes. Hepatocytes ingested both Lf forms-determined by  
EGTA/dextran sulfate removal of surface-bound Lf-at maximal endocytic  
rates of 1.85 and 1.52 fmol cell<sup>-1</sup> min<sup>-1</sup> for I-125-apo-Lf and  
I-125-holo-Lf, respectively. First-order endocytic rate constants  
(37-degrees-C) for I-125-apo-Lf and I-125-holo-Lf were 0.276 and 0.292  
min<sup>-1</sup>, respectively. Regardless of Lf's iron content, hyperosmotic media  
(approximately 500 mmol/kg) inhibited Lf uptake by approximately 90%,  
indicating endocytosis of both Lf forms was primarily clathrin-dependent.  
Endocytosis of both Lf forms was not altered significantly in the presence  
of excess iron chelator desferrioxamine or rat holo-transferrin, or by  
cycloheximide treatment. Fluorescein isothiocyanate- and cyclohexanedione-  
**modified** Lf competed fully with native Lf for binding and  
endocytosis, indicating that, unlike human Lf, modification of lysine or  
arginine residues does not block the interaction of bovine Lf with cells.  
After binding Lf at 4-degrees-C, cells at 37-degrees-C internalized  
approximately 90% of Lf bound to Ca<sup>2+</sup>-dependent sites but not Lf bound to  
Ca<sup>2+</sup>-independent sites. Following uptake, hepatocytes released  
acid-soluble (degraded) products of I-125-Lf biphasically at 37-degrees-C,  
an initial rapid phase within the first 20 min-more pronounced with  
I-125-holo-Lf-followed by a sustained linear release of 298 and 355  
molecule equiv cell<sup>-1</sup> min<sup>-1</sup> for I-125-apo-Lf and I-125-holo-Lf,  
respectively. At 4-degrees-C, both digitonin-permeabilized and intact  
cells bound approximately 1.1 x 10<sup>(6)</sup> I-125-Lf molecules to Ca<sup>2+</sup>-dependent  
sites per cell, indicating that hepatocytes do not contain a sizeable  
intracellular pool of these sites. Moreover, cells retained >70% of  
Ca<sup>2+</sup>-dependent sites on the surface during sustained Lf endocytosis. Thus,  
these Lf binding sites recycle during endocytosis at an estimated 4-5  
min/circuit.

=> s 136 and heterologous amino acid sequence  
L38 0 L36 AND HETEROLOGOUS AMINO ACID SEQUENCE

=> d 136 1-124 cbib

L36 ANSWER 1 OF 124 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
2002:309756 Document No.: PREV200200309756. A comparison of pravastatin and  
gemfibrozil in the treatment of dyslipoproteinemia in patients with

non-insulin-dependent diabetes mellitus. Schweitzer, Morris (1); Tessier, Daniel; Vlahos, William D.; Leiter, Lawrence; Collet, Jean Paul; McQueen, Matthew J.; Harvey, Laurent; Alaupovic, Petar. (1) Sir Mortimer B. Davis-Jewish General Hospital, 3755 Cote-Ste-Catherine Rd, Montreal, Que., H3T 1E2: putch@total.net Canada. Atherosclerosis, (May, 2002) Vol. 162, No. 1, pp. 201-210. <http://www.elsevier.com/locate/atherosclerosis>. print. ISSN: 0021-9150. Language: English.

L36 ANSWER 2 OF 124 MEDLINE DUPLICATE 1  
2001694738 Document Number: 21607569. PubMed ID: 11742873. Arg123-Tyr166 domain of human ApoA-I is critical for HDL-mediated inhibition of macrophage homing and early atherosclerosis in mice. Holvoet P; Peeters K; Lund-Katz S; Mertens A; Verhamme P; Quarck R; Stengel D; Lox M; Deridder E; Bernar H; Nickel M; Theilmeier G; Ninio E; Phillips M C. (Center for Experimental Surgery and Anesthesiology, Katholieke Universiteit Leuven, Leuven, Belgium.. paul.holvoet@med.kuleuven.ac.be) . ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, (2001 Dec) 21 (12) 1977-83. Journal code: 9505803. ISSN: 1524-4636. Pub. country: United States. Language: English.

L36 ANSWER 3 OF 124 CAPLUS COPYRIGHT 2002 ACS  
2000:422773 Document No. 133:131309 Identification of domains in apoA-I susceptible to proteolysis by mast cell chymase: implications for HDL function. Lee, Miriam; Uboldi, Patrizia; Giudice, Daniela; Catapano, Alberico L.; Kovanen, Petri T. (Wihuri Research Institute, Helsinki, 00140, Finland). Journal of Lipid Research, 41(6), 975-984 (English) 2000. CODEN: JLPRAW. ISSN: 0022-2275. Publisher: Lipid Research, Inc..

L36 ANSWER 4 OF 124 MEDLINE DUPLICATE 2  
2000069736 Document Number: 20069736. PubMed ID: 10601312. Molecular cloning, characterization, and expression of a novel human neutral sphingomyelinase. Chatterjee S; Han H; Rollins S; Cleveland T. (Department of Pediatrics, Johns Hopkins Hospital, Baltimore, Maryland 21287-3654, USA.. chatter@welchlink.welch.jhu.edu) . JOURNAL OF BIOLOGICAL CHEMISTRY, (1999 Dec 24) 274 (52) 37407-12. Journal code: 2985121R. ISSN: 0021-9258. Pub. country: United States. Language: English.

L36 ANSWER 5 OF 124 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
1999:419977 Document No.: PREV199900419977. The Bezafibrate Infarction Prevention (BIP) Study, Israel: HDL subclasses (HDL2 HDL3, LpAI LpAI:AI), in CHD patients compared to healthy individuals. Graff, Eran (1); Schwartz, Sara; Schwartz, Shoshana; Boaz, Mona; Brunner, Daniel. (1) Tel-Aviv E. Sourasky Med. Center, Tel-Aviv Israel. Journal of the American College of Cardiology, (Feb., 1999) Vol. 33, No. 2 SUPPL. A, pp. 271A-272A. Meeting Info.: 48th Annual Scientific Session of the American College of Cardiology New Orleans, Louisiana, USA March 7-10, 1999 American College of Cardiology. ISSN: 0735-1097. Language: English.

L36 ANSWER 6 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1998:663330 Document No. 130:21298 The nuclear receptors peroxisome proliferator-activated receptor .alpha. and Rev-erb.alpha. mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. Vu-Dac, Ngoc; Chopin-Delannoy, Sandrine; Gervois, Philippe; Bonnelye, Edith; Martin, Genevieve; Fruchart, Jean-Charles; Laudet, Vincent; Staels, Bart (U.325 INSERM, Department d'Atherosclerose, Institut Pasteur, and the Faculte de Pharmacie, Universite de Lille II, Lille, Fr.). Journal of Biological Chemistry, 273(40), 25713-25720 (English) 1998. CODEN: JBCHA3. ISSN: 0021-9258. Publisher: American Society for Biochemistry and Molecular Biology.

L36 ANSWER 7 OF 124 MEDLINE  
1998388368 Document Number: 98388368. PubMed ID: 9721473. [Fatty acid composition of phosphatidylcholine and levels of lipids and



**lipoproteins** in hyperlipoproteinemia. I. Relation to HDL **lipoprotein**]. Slozeni mastnych kyselin plazmatickeho fosfatidylcholinu a koncentrace lipidu a lipoproteinu u hyperlipoproteinemii. I. Vztahy k lipoproteinu HDL. Zak A; Zeman M; Tvrzicka E. (IV. interni klinika I. LF UK a VFN, Praha. ) CASOPIS LEKARU CESKYCH, (1998 Jun 15) 137 (12) 368-71. Journal code: 0004743. ISSN: 0008-7335. Pub. country: Czech Republic. Language: Czech.

L36 ANSWER 8 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1998:284571 Document No. 129:66080 Mechanisms of high density **lipoprotein**-mediated efflux of cholesterol from cell plasma membranes. Phillips, Michael C.; Gillotte, Kristin L.; Haynes, M. Page; Johnson, William J.; Lund-Katz, Sissel; Rothblat, George H. (MCP-Hahnemann School of Medicine, Biochemistry Department, Allegheny University of the Health Sciences, 2900 Queen Lane, Philadelphia, PA, 19129, USA). Atherosclerosis (Shannon, Ireland), 137(Suppl.), s13-s17 (English) 1998. CODEN: ATHSBL. ISSN: 0021-9150. Publisher: Elsevier Science Ireland Ltd..

L36 ANSWER 9 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1998:24742 Document No. 128:126594 Turnover of pro- and mature apolipoprotein A-I in diabetic patients and normolipidemic controls. Gallager, John J.; Gray, Robert M.; Bannister, Peter A.; Chrisoulidou, Alexandra; Robinson, Adam C. J.; Johnston, Desmond G.; Venkatesan, Soundararajan (Unit of Metabolic Medicine, Imperial College School of Medicine at St Mary's, London, W2 1PG, UK). Biochemical Society Transactions, 25(4), S686 (English) 1997. CODEN: BCSTB5. ISSN: 0300-5127. Publisher: Portland Press Ltd..

L36 ANSWER 10 OF 124 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
1998047730 EMBASE Efficacy and safety of fluvastatin in patients with non-insulin- dependent diabetes mellitus and hypercholesterolemia. Ding P.Y.-A.; Sheu W.H.-H.; Hu C.-A.; Pei D.. Dr. P.Y.-A. Ding, Division of Cardiology, Department of Medicine, Veterans General Hospital, Shih-Pai Road, Taipei 100, Taiwan, Province of China. Acta Cardiologica Sinica 13/3 (138-144) 1997.  
Refs: 24.  
ISSN: 1011-6842. CODEN: CKHCE3. Pub. Country: Taiwan, Province of China. Language: English. Summary Language: English; Chinese.

L36 ANSWER 11 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1996:130547 Document No. 124:168765 The influence of sphingomyelin on the structure and function of reconstituted high density **lipoproteins**. Rye, Kerry-Anne; Hime, Neil J.; Barter, Philip J. (Division Cardiovascular Services, University Adelaide, Adelaide, 5000, Australia). Journal of Biological Chemistry, 271(8), 4243-50 (English) 1996. CODEN: JBCHA3. ISSN: 0021-9258. Publisher: American Society for Biochemistry and Molecular Biology.

L36 ANSWER 12 OF 124 SCISEARCH COPYRIGHT 2002 ISI (R)  
96:655166 The Genuine Article (R) Number: VE876. LOW-DENSITY-**LIPOPROTEIN** RECEPTOR-RELATED PROTEIN-2 EXPRESSION IN EFFERENT DUCT AND EPIDIDYMAL EPITHELIA - EVIDENCE IN RATS FOR ITS IN-VIVO ROLE IN ENDOCYTOSIS OF APOLIPOPROTEIN J/CLUSTERIN. MORALES C R (Reprint); IGDOURA S A; WOSU U A; BOMAN J; ARGRAVES W S. MCGILL UNIV, DEPT ANAT & CELL BIOL, 3640 UNIV ST, MONTREAL, PQ H3A 2B2, CANADA (Reprint); MED UNIV S CAROLINA, DEPT CELL BIOL & ANAT, CHARLESTON, SC, 29425. BIOLOGY OF REPRODUCTION (SEP 1996) Vol. 55, No. 3, pp. 676-683. ISSN: 0006-3363. Pub. country: CANADA; USA. Language: ENGLISH.  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L36 ANSWER 13 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1996:143952 Document No. 124:198525 Insect hemocyte adhesion in vitro:

inhibition by apolipoporphyrin I and an artificial substrate. Mandato, C. A.; Diehl-Jones, W. L.; Downer, R. G. H. (Dep. Biol., Univ. Waterloo, Waterloo, ON, N2L 3G1, Can.). Journal of Insect Physiology, 42(2), 143-8 (English) 1996. CODEN: JIPHAF. ISSN: 0022-1910. Publisher: Elsevier.

L36 ANSWER 14 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1995:772802 Document No. 123:160855 Use of thalidomide for treating neurocognitive disorders. Andrulis, Peter J., Jr. (Andrulis Pharmaceuticals Corp., USA). PCT Int. Appl. WO 9517154 A2 19950629, 23 pp. DESIGNATED STATES: W: AU, CA, CN, JP; RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (English). CODEN: PIXXD2. APPLICATION: WO 1994-US14743 19941222. PRIORITY: US 1993-172155 19931223.

L36 ANSWER 15 OF 124 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
95308404 EMBASE Document No.: 1995308404. G.fwdarw.A substitution at position -75 of the apolipoprotein A-I gene promoter: Evidence against a direct effect on HDL cholesterol levels. Minnich A.; DeLangavant G.; Lavigne J.; Roederer G.; Lussier-Cacan S.; Davignon J.. Clinical Research Inst. of Montreal, 110 Pine Avenue, West, Montreal, Que. H2W 1R7, Canada. Arteriosclerosis, Thrombosis, and Vascular Biology 15/10 (1740-1745) 1995. ISSN: 1079-5642. CODEN: ATVBFA. Pub. Country: United States. Language: English. Summary Language: English.

L36 ANSWER 16 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1995:832017 Document No. 123:253324 ApoA-IHelsinki (Lys107 .fwdarw. 0) associated with reduced HDL cholesterol and LpA-I:A-II deficiency. Tilly-Kiesi, Marju; Qiuping, Zhang; Ehnholm, Sonja; Kahri, Juhani; Lahdenpera, Sanni; Ehnholm, Christian; Taskinen, Marja-Riitta (Dep. Med., Helsinki Univ. Central Hospital, Helsinki, FIN-00290, Finland). Arteriosclerosis, Thrombosis, and Vascular Biology, 15(9), 1294-306 (English) 1995. CODEN: ATVBFA. ISSN: 1079-5642. Publisher: American Heart Association.

L36 ANSWER 17 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1995:676577 Document No. 123:78867 Capillary electrophoresis of human serum proteins and apolipoproteins. Lehmann, Rainer; Liebich, Hartmut; Gruebler, Gerald; Voelter, Wolfgang (Abteilung IV Endokrinologie und Klinische Chemie, Universitaet Tuebingen, Tuebingen, Germany). Electrophoresis, 16(6), 998-1001 (English) 1995. CODEN: ELCTDN. ISSN: 0173-0835. Publisher: VCH.

L36 ANSWER 18 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1995:297903 Document No. 122:51789 Human apolipoprotein E mediates processive buoyant **lipoprotein** formation in insect larvae. Gretch, Daniel G.; Sturley, Stephen L.; Attie, Alan D. (Department of Biochemistry, University of Wisconsin-Madison, Madison, WI, 53706, USA). Biochemistry, 34(2), 545-52 (English) 1995. CODEN: BICHAW. ISSN: 0006-2960. Publisher: American Chemical Society.

L36 ANSWER 19 OF 124 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
95095855 EMBASE Document No.: 1995095855. Plasma lipid transport in the hedgehog: Partial characterization of structure and function of apolipoprotein A-I. Sparrow D.A.; Laplaud P.M.; Saboureau M.; Zhou G.; Dolphin P.J.; Gotto Jr. A.M.; Sparrow J.T.. Unite 321 INSERM, Pavillon Benjamin Delessert, Hopital de la Pitie, 83 boulevard de l'Hopital, 75651 Paris Cedex 13, France. Journal of Lipid Research 36/3 (485-495) 1995. ISSN: 0022-2275. CODEN: JLPRAW. Pub. Country: United States. Language: English. Summary Language: English.

L36 ANSWER 20 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1995:581596 Document No. 122:313543 The accumulation of hemolymph proteins and activity of digestive proteinases of grasshoppers (Melanoplus

sanguinipes) fed wheat, oats or kochia. Hinks, C. F.; Erlandson, M. A. (Agriculture Canada Res. Station, Saskatoon, S7N 0X2, Can.). Journal of Insect Physiology, 41(5), 425-33 (English) 1995. CODEN: JIPHAF. ISSN: 0022-1910. Publisher: Elsevier.

L36 ANSWER 21 OF 124 CAPLUS COPYRIGHT 2002 ACS

1995:528356 Document No. 122:287019 Isolation and characterization of serum **lipoproteins** in red sea bream. Iijima, Noriaki; Gotou, Takanobu; Kayama, Mitsu (Fac. Applied Biol. Sci., Hiroshima Univ., Hiroshima, 724, Japan). Fisheries Science, 61(2), 297-303 (English) 1995. CODEN: FSCIEH. ISSN: 0919-9268. Publisher: Japanese Society of Fisheries Science.

L36 ANSWER 22 OF 124 CAPLUS COPYRIGHT 2002 ACS

1995:328206 Document No. 122:126838 Structural studies of Manduca sexta lipid transfer particle with apolipoprotein-specific antibodies. Blacklock, Brenda, J.; Ryan, Robert O. (Department Biochemistry, University Alberta, Edmonton, AB, T6G 2S2, Can.). Journal of Lipid Research, 36(1), 108-16 (English) 1995. CODEN: JLPRAW. ISSN: 0022-2275. Publisher: Lipid Research, Inc..

L36 ANSWER 23 OF 124 CAPLUS COPYRIGHT 2002 ACS

1995:230392 Document No. 122:73811 Transcriptional regulation of the apolipoprotein A-IV gene involves synergism between a proximal orphan receptor response element and a distant enhancer located in the upstream promoter region of the apolipoprotein C-III gene. Ktistaki, Eleni; Lacorte, Jean-Marc; Katrakili, Nitsa; Zannis, Vassilis I.; Talianidis, Iannis (Medical School, University Crete, Crete, 711 10, Greece). Nucleic Acids Research, 22(22), 4689-96 (English) 1994. CODEN: NARHAD. ISSN: 0305-1048. Publisher: Oxford University Press.

L36 ANSWER 24 OF 124 CAPLUS COPYRIGHT 2002 ACS

1994:553654 Document No. 121:153654 Lipophorin as a lipid carrier in the hemolymph of the horseshoe crab, Limulus polyphemus. Rehn, K. G.; Lee, R. F. (Centro de Ciencias Biologicas, Universidade Federal de Pernambuco, Recife, 50732-970, Brazil). Brazilian Journal of Medical and Biological Research, 27(5), 1135-9 (English) 1994. CODEN: BJMRDK. ISSN: 0100-879X.

L36 ANSWER 25 OF 124 CAPLUS COPYRIGHT 2002 ACS

1995:285929 Document No. 122:104707 Effects of a diet restricted in saturated fatty acids and cholesterol on the composition of apolipoprotein A-I-containing **lipoprotein** particles in the fasting and fed states. Cheung, Marian C.; Lichtenstein, Alice H.; Schaefer, Ernst J. (Department Medicine, University Washington, Seattle, WA, 98103, USA). American Journal of Clinical Nutrition, 60(6), 911-18 (English) 1994. CODEN: AJCNAC. ISSN: 0002-9165.

L36 ANSWER 26 OF 124 CAPLUS COPYRIGHT 2002 ACS

1994:504586 Document No. 121:104586 Triglyceride-rich lipophorin in Aedes aegypti (Diptera: Culicidae). Ford, Pamela S.; Van Heusden, Miranda C. (Dep. Biochem., Univ. Arizona, Tucson, AZ, 85721, USA). Journal of Medical Entomology, 31(3), 435-41 (English) 1994. CODEN: JMENA6. ISSN: 0022-2585.

L36 ANSWER 27 OF 124 CAPLUS COPYRIGHT 2002 ACS

1994:293380 Document No. 120:293380 Capillary gel electrophoresis analysis of apolipoproteins A-I and A-II in human high-density **lipoproteins**. Goux, Alain; Athias, Anne; Persegol, Laurence; Lagrost, Laurent; Gambert, Philippe; Lallemand, Christian (Lab. Biochim. Lipoproteines, Fac. Med., Dijon, Fr.). Analytical Biochemistry, 218(2), 320-4 (English) 1994. CODEN: ANBCA2. ISSN: 0003-2697.

L36 ANSWER 28 OF 124 MEDLINE  
95208286 Document Number: 95208286.

DUPLICATE 3  
PubMed ID: 7900356. [The lipid

metabolic indices of patients with different outcomes in unstable anginal.  
Pokazateli lipidnogo obmena u bol'nykh s razlichnym iskhodom nestabil'noi  
stenokardii. Kazimova L F; Tseluiko V I. LIKARSKA SPRAVA, (1994 Jul-Aug)  
(7-8) 56-9. Journal code: 9601540. ISSN: 1019-5297. Pub. country:  
Ukraine. Language: Russian.

L36 ANSWER 29 OF 124 CAPLUS COPYRIGHT 2002 ACS

1994:319719 Document No. 120:319719 Aedes aegypti lipophorin. de L.  
Capurro, M.; de Bianchi, A. G.; Marinotti, O. (Inst. Quim., Univ. Sao  
Paulo, Sao Paulo, 01498, Brazil). Comparative Biochemistry and  
Physiology, Part B: Biochemistry & Molecular Biology, 108B(1), 35-9  
(English) 1994. CODEN: CBPBB8. ISSN: 0305-0491.

L36 ANSWER 30 OF 124 SCISEARCH COPYRIGHT 2002 ISI (R)

93:736313 The Genuine Article (R) Number: MM035. ENDOCYTOSIS AND DEGRADATION  
OF BOVINE APO-LACTOFERRIN AND HOLO-LACTOFERRIN BY ISOLATED RAT HEPATOCYTES  
ARE MEDIATED BY RECYCLING CALCIUM-DEPENDENT BINDING-SITES. MCABEE D D  
(Reprint); NOWATZKE W; OEHLER C; SITARAM M; SBASCHNIG E; OFFERMAN J T;  
CARR J; ESBENSEN K. UNIV NOTRE DAME, DEPT BIOL SCI, NOTRE DAME, IN, 46556  
(Reprint). BIOCHEMISTRY (14 DEC 1993) Vol. 32, No. 49, pp. 13749-13760.  
ISSN: 0006-2960. Pub. country: USA. Language: ENGLISH.  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L36 ANSWER 31 OF 124 CAPLUS COPYRIGHT 2002 ACS

1993:165508 Document No. 118:165508 Biosynthesis of locust lipophorin.  
Apolipophorins I and II originate from a common precursor. Weers, Paul M.  
M.; Van Marrewijk, Wil J. A.; Beenackers, Ad M. T.; Van der Horst, Dick J.  
(Dep. Exp. Zool., Univ. Utrecht, Utrecht, 3508 TB, Neth.). Journal of  
Biological Chemistry, 268(6), 4300-3 (English) 1993. CODEN: JBCHA3.  
ISSN: 0021-9258.

L36 ANSWER 32 OF 124 CAPLUS COPYRIGHT 2002 ACS

1994:28712 Document No. 120:28712 Hypertriglyceridemia and cholesteryl ester  
transfer protein interact to dramatically alter high density  
**lipoprotein** levels, particle sizes, and metabolism: studies in  
transgenic mice. Hayek, Tony; Azrolan, Neal; Verdery, Roy B.; Walsh,  
Annemarie; Chajek-Shaul, Tova; Agellon, Luis B.; Tall, Alan R.; Breslow,  
Jan L. (Lab. Biochem. Genet. Metab., Rockefeller Univ., New York, NY,  
10021-6399, USA). Journal of Clinical Investigation, 92(3), 1143-52  
(English) 1993. CODEN: JCINAO. ISSN: 0021-9738.

L36 ANSWER 33 OF 124 CAPLUS COPYRIGHT 2002 ACS

1993:601425 Document No. 119:201425 Detection of anticardiolipin antibody  
using the EIA kit prepared to eliminate interference of serum cofactor.  
Nagano, Yuriko; Yoshinoya, Sadayoshi; Ohkubo, Akiyuki (Fac. Med., Univ.  
Tokyo, Tokyo, 113, Japan). Rinsho Byori, 41(8), 907-13 (Japanese) 1993.  
CODEN: RBYOAI. ISSN: 0047-1860.

L36 ANSWER 34 OF 124 CAPLUS COPYRIGHT 2002 ACS

1993:667045 Document No. 119:267045 Biosynthetic route of locust  
apolipophorin III isoforms. Weers, Paul M. M.; Van Baal, Juergen; Van  
Doorn, Jan M.; Ziegler, Rolf; Van der Horst, Dick J. (Dep. Exp. Zool,  
Univ. Utrecht, Neth.). Biological Chemistry Hoppe-Seyler, 374(9), 863-9  
(English) 1993. CODEN: BCHSEI. ISSN: 0177-3593.

L36 ANSWER 35 OF 124 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

1993:251592 Document No.: PREV199395130767. Characterization of the  
apolipoprotein AI and CIII genes in the domestic pig. Birchbauer, Andrea;  
Knipping, Gabriele; Juritsch, Birgit; Aschauer, Heinrich; Zechner, Rudolf  
(1). (1) Inst. Med. Biochem., Univ. Graz, Harrachgasse 21, A-8010 Graz  
Austria. Genomics, (1993) Vol. 15, No. 3, pp. 643-652. ISSN: 0888-7543.  
Language: English.

- L36 ANSWER 36 OF 124 CAPLUS COPYRIGHT 2002 ACS  
 1993:122144 Document No. 118:122144 Coronary artery disease risk predicted by plasma concentrations of high-density **lipoprotein** cholesterol, apolipoprotein AI, apolipoprotein B, and **lipoprotein** (a) in a general Chinese population. Wu, June Hsieh; Kao, Jau Tsuen; Wen, Ming Shien; Wu, Delon (Mol. Genet. Lab., Chang-Gung Med. Coll., Taoyuan, Taiwan). Clinical Chemistry (Washington, DC, United States), 39(2), 209-12 (English) 1993. CODEN: CLCHAU. ISSN: 0009-9147.
- L36 ANSWER 37 OF 124 CAPLUS COPYRIGHT 2002 ACS  
 1993:189263 Document No. 118:189263 Metabolism of DHL particles LpA-I and LpA-I, A-II in normal and hyperalphalipoproteinemic subjects. Rader, Daniel J.; Ikewaki, Katsunori; Schaefer, Juergen R.; Brewer, Bryan H. (Natl. Inst. Health, Bethesda, MD, 20892, USA). Atherosclerosis Reviews, 24(High Density Lipoproteins), 43-55 (English) 1993. CODEN: ATHEDF. ISSN: 0362-1650.
- L36 ANSWER 38 OF 124 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
 1992:525072 Document No.: BA94:133147. PHYSIOLOGIC MECHANISMS FOR REDUCED APOLIPOPROTEIN A-I CONCENTRATIONS ASSOCIATED WITH LOW LEVELS OF HIGH DENSITY **LIPOPROTEIN** CHOLESTEROL IN PATIENTS WITH NORMAL PLASMA LIPIDS. GYLLING H; VEGA G L; GRUNDY S M. CENT. HUM. NUTR., 5323 HARRY HINES BLVD., DALLAS, TEX. 75235-9052, USA.. J LIPID RES, (1992) 33 (10), 1527-1539. CODEN: JLPRAW. ISSN: 0022-2275. Language: English.
- L36 ANSWER 39 OF 124 CAPLUS COPYRIGHT 2002 ACS  
 1992:610170 Document No. 117:210170 Effects of intralipid-induced hypertriglyceridemia on plasma high-density **lipoprotein** metabolism in the cynomolgus monkey. Goldberg, Ira J.; Vanni, Teresa M.; Ramakrishnan, Rajasekhar (Coll. Physic. Surg., Columbia Univ., New York, NY, 10032, USA). Journal of Chromatography, 580(1-2), 1176-84 (English) 1992. CODEN: JOCRAM. ISSN: 0021-9673.
- L36 ANSWER 40 OF 124 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
 92065124 EMBASE Document No.: 1992065124. Modulation of **lipoprotein** production in HEP G2 cells by fenofibrate and clofibrate. Hahn S.E.; Goldberg D.M.. Dept. Clinical Biochemistry, University of Toronto, 100 College Street, Toronto, Ont. M5G 1L5, Canada. Biochemical Pharmacology 43/3 (625-633) 1992. ISSN: 0006-2952. CODEN: BCPA6. Pub. Country: United Kingdom. Language: English. Summary Language: English.
- L36 ANSWER 41 OF 124 CAPLUS COPYRIGHT 2002 ACS  
 1992:404513 Document No. 117:4513 Biosynthesis and secretion of insect **lipoprotein**. Weers, Paul M. M.; Van der Horst, Dick J.; Van Marrewijk, Wil J. A.; Van den Eijnden, Mark; Van Doorn, Jan M.; Beenackers, A. M. T. (Dep. Exp. Zool., Univ. Utrecht, Utrecht, 3508 TB, Neth.). Journal of Lipid Research, 33(4), 485-91 (English) 1992. CODEN: JLPRAW. ISSN: 0022-2275.
- L36 ANSWER 42 OF 124 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
 1992:211262 Document No.: BA93:111487. POLYMORPHISMS IN THE APOLIPOPROTEIN APO AI-CIII-AIV GENE CLUSTER DETECTION OF GENETIC VARIATION DETERMINING PLASMA APO AI APO CIII AND APO AIV CONCENTRATIONS. PAUL-HAYASE H; ROSSENEU M; ROBINSON D; VAN BERVLIET J P; DESLYPERE J P; HUMPHRIES S E. CHARING CROSS SUNLEY RES. CENTRE, 1 LURGAN AVE., HAMMERSMITH, LONDON W6 8LW.. HUM GENET, (1992) 88 (4), 439-446. CODEN: HUGEDQ. ISSN: 0340-6717. Language: English.
- L36 ANSWER 43 OF 124 CAPLUS COPYRIGHT 2002 ACS  
 1993:121492 Document No. 118:121492 Determinants of HDL metabolism in subjects with low HDL-C levels. Brinton, Eliot A.; Eisenberg, Shlomo; Breslow, Jan L. (Rockefeller Univ., New York, NY, 10021, USA). International Congress Series, 1001(High Density Lipoproteins Atheroscler.

III), 207-13 (English) 1992. CODEN: EXMDA4. ISSN: 0531-5131.

L36 ANSWER 44 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1992:402897 Document No. 117:2897 The role of apoproteins AI and AII in binding of high-density lipoprotein3 to membranes derived from bovine aortic endothelial cells. Vadiveloo, Peter K.; Fidge, Noel H. (Baker Med. Res. Inst., Prahran, 3181, Australia). Biochemical Journal, 284(1), 145-51 (English) 1992. CODEN: BIJOAK. ISSN: 0306-3275.

L36 ANSWER 45 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1992:191345 Document No. 116:191345 Assembly and secretion of lipophorin by the larval fat body of the southwestern corn borer, *Diatraea grandiosella*: an in vitro study [Erratum to document cited in CA116(5):38283w]. Shelby, Kent S.; Chippendale, G. Michael (Dep. Entomol., Univ. Missouri, Columbia, MO, 65211, USA). Archives of Insect Biochemistry and Physiology, 19(2), 145 (English) 1992. CODEN: AIBPEA. ISSN: 0739-4462.

L36 ANSWER 46 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1992:101437 Document No. 116:101437 Effect of particle lipid content on the structure of insect lipophorins. Ryan, Robert O.; Kay, Cyril M.; Oikawa, Kim; Liu, Hu; Bradley, Roger; Scraba, Douglas G. (Dep. Biochem., Univ. Alberta, Edmonton, AB, T6G 2S2, Can.). Journal of Lipid Research, 33(1), 55-63 (English) 1992. CODEN: JLPRAW. ISSN: 0022-2275.

L36 ANSWER 47 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1992:148534 Document No. 116:148534 Insect lipophorin conversions: compositional analysis of high- and low-density lipophorin of *Acherontia atropos* and *Locusta migratoria*. Surholt, Bernhard; Van Doorn, Jan M.; Goldberg, Jutta; Van der Horst, Dick J. (Inst. Zoophysiol., Univ. Muenster, Muenster, W-4400, Germany). Biological Chemistry Hoppe-Seyler, 373(1), 13-20 (English) 1992. CODEN: BCHSEI. ISSN: 0177-3593.

L36 ANSWER 48 OF 124 SCISEARCH COPYRIGHT 2002 ISI (R)  
91:537791 The Genuine Article (R) Number: GG553. TRANSCRIPTIONAL REGULATION OF THE APOLIPOPROTEIN A-I GENE - SPECIES-SPECIFIC EXPRESSION CORRELATES WITH RATES OF GENE-TRANSCRIPTION. SORCITHOMAS M (Reprint); KEARNS M W. WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT COMPARAT MED, 300 S HAWTHORNE RD, WINSTON SALEM, NC, 27103 (Reprint); WAKE FOREST UNIV, BOWMAN GRAY SCH MED, ATHEROSCLEROSIS RES CTR, WINSTON SALEM, NC, 27103. JOURNAL OF BIOLOGICAL CHEMISTRY (1991) Vol. 266, No. 27, pp. 18045-18050. Pub. country: USA. Language: ENGLISH.  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L36 ANSWER 49 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1991:577669 Document No. 115:177669 Structure of Colorado potato beetle lipophorin: differential scanning calorimetric and small-angle x-ray scattering studies. Katagiri, Chihiro; Sato, Mamoru; De Kort, Stan; Katsube, Yukiteru (Inst. Low Temp. Sci., Hokkaido Univ., Sapporo, Japan). Biochemistry, 30(40), 9675-81 (English) 1991. CODEN: BICHAW. ISSN: 0006-2960.

L36 ANSWER 50 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1992:17468 Document No. 116:17468 Lipophorin structure analyzed by in vitro treatment with lipases. Kawooya, John K.; Van der Horst, Dick J.; Van Heusden, Miranda C.; Brigot, Bernadette L. J.; Van Antwerpen, Rik; Law, John H. (Cent. Insect Sci., Univ. Arizona, Tucson, AZ, 85721, USA). Journal of Lipid Research, 32(11), 1781-8 (English) 1991. CODEN: JLPRAW. ISSN: 0022-2275.

L36 ANSWER 51 OF 124 SCISEARCH COPYRIGHT 2002 ISI (R) DUPLICATE 4  
91:286865 The Genuine Article (R) Number: FL004. A SCANNING TUNNELING MICROSCOPY STUDY OF AN INSECT LIPOPROTEIN ICE NUCLEATOR. YEUNG K L; WOLF E E (Reprint); DUMAN J G. UNIV NOTRE DAME, DEPT CHEM ENGN, NOTRE

DAME, IN, 46556; UNIV NOTRE DAME, DEPT BIOL SCI, NOTRE DAME, IN, 46556.  
JOURNAL OF VACUUM SCIENCE & TECHNOLOGY B (1991) Vol. 9, No. 2, pp.  
1197-1201. Pub. country: USA. Language: ENGLISH.  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

L36 ANSWER 52 OF 124 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
1992:264252 Document No.: BA93:140577. RELATIONS OF SERUM APOLIPOPROTEIN A-I  
A-II B LEVELS TO SMOKING DRINKING AND BODY MASS. TAKASHIMA Y; AKAMATSU T;  
ORIDO Y; KINOUE T; TSUNODA T; TERUYA K; TSUGANE S; WATANABE S. DEP. PUBLIC  
HEALTH, KYORIN UNIVERSITY SCHOOL MEDICINE, TOKYO.. JPN J HYG, (1991) 46  
(5), 994-1008. CODEN: NEZAAQ. ISSN: 0021-5082. Language: Japanese.

L36 ANSWER 53 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1991:652370 Document No. 115:252370 Lipophorin from the tsetse fly, *Glossina*  
*morsitans morsitans*. Ochanda, James O.; Osir, Ellie O.; Nguu, Edward K.;  
Olembo, Norah K. (Dep. Biochem., Univ. Nairobi, Nairobi, Kenya). Comp.  
Biochem. Physiol., B: Comp. Biochem., 99B(4), 811-14 (English) 1991.  
CODEN: CBPBB8. ISSN: 0305-0491.

L36 ANSWER 54 OF 124 MEDLINE DUPLICATE 5  
92106840 Document Number: 92106840. PubMed ID: 1762457. [Glycemic control  
and **lipoprotein** profile in type I diabetes mellitus]. Control  
glucemico y perfil lipoproteico en la diabetes mellitus tipo I. Garcia  
Pascual L; Mesa Manteca J; Obiols Alfonso G; Chacon Castro P; Campos  
Barreda F; Simo Canonge R. (Seccion de Endocrinologia, Hospital General  
Vall d'Hebron, Barcelona. ) MEDICINA CLINICA, (1991 Nov 16) 97 (17) 645-9.  
Journal code: 0376377. ISSN: 0025-7753. Pub. country: Spain. Language:  
Spanish.

L36 ANSWER 55 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1992:56274 Document No. 116:56274 Changes in serum lipid and  
**lipoprotein** measures after maximal exercise in men. Cordova, A.;  
Rabadan, L.; Escanero, J. F. (Dep. Physiol. Biochem., Univ. Valladolid,  
Soria, 42003, Spain). Journal of International Medical Research, 19(6),  
465-70 (English) 1991. CODEN: JIMRBV. ISSN: 0300-0605.

L36 ANSWER 56 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1991:201997 Document No. 114:201997 Study on the composition-structure  
relationship of lipophorins. Soulages, Jose L.; Brenner, Rodolfo R. (Fac.  
Cienc. Med., UNLP, La Plata, 1900, Argent.). J. Lipid Res., 32(3), 407-15  
(English) 1991. CODEN: JLPRAW. ISSN: 0022-2275.

L36 ANSWER 57 OF 124 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
1991:462737 Document No.: BR41:88497. HIGH DENSITY **LIPOPROTEINS** AND  
CORONARY HEART DISEASE. BARTER P J. DEP. PREVENTIVE CARDIOL. GRADUATE SCH.  
HEALTH MED. SCI., UNIV. WOLLONGONG, P.O. BOX 1144, WOOLLONGONG, NSW 2500,  
AUSTRALIA.. Aust. N. Z. J. Med., (1991) 21 (3), 299-301. CODEN: ANZJB8.  
ISSN: 0004-8291. Language: English.

L36 ANSWER 58 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1991:177873 Document No. 114:177873 Inhibition of virus-induced cell fusion  
by apolipoprotein A-I and its amphipathic peptide analogs. Srinivas, R.  
V.; Venkatachalapathi, Y. V.; Rui, Zheng; Owens, R. J.; Gupta, K. B.;  
Srinivas, S. K.; Anantharamaiah, G. M.; Segrest, J. P.; Compans, R. W.  
(Dep. Microbiol., Univ. Alabama, Birmingham, AL, 35294, USA). J. Cell.  
Biochem., 45(2), 224-37 (English) 1991. CODEN: JCEBD5. ISSN: 0730-2312.

L36 ANSWER 59 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1992:38283 Document No. 116:38283 Assembly and secretion of lipophorin by  
the larval fat body of the southwestern corn borer, *Diatraea grandiosella*:  
an in vitro study. Shelby, Kent S.; Chippendale, G. Michael (Dep.  
Entomol., Univ. Missouri, Columbia, MO, 65211, USA). Archives of Insect  
Biochemistry and Physiology, 18(4), 203-17 (English) 1991. CODEN: AIBPEA.

ISSN: 0739-4462.

- L36 ANSWER 60 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1991:142022 Document No. 114:142022 Intestinal apolipoprotein synthesis in the newborn piglet. Black, Dennis D.; Rohwer-Nutter, Patricia L. (Pritzker Sch. Med., Univ. Chicago, Chicago, IL, 60637, USA). *Pediatr. Res.*, 29(1), 32-8 (English) 1991. CODEN: PEREBL. ISSN: 0031-3998.
- L36 ANSWER 61 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1990:421046 Document No. 113:21046 The hemolymph of the midge *Chironomus thummi* contains both a high and a low molecular weight juvenile hormone-binding protein. Wisniewski, Jacek R.; Steuernagel, Arnd (III. Zool. Inst. Entwicklungsbiol., Univ. Goettingen, Goettingen, D-3400, Fed. Rep. Ger.). *Comp. Biochem. Physiol., B: Comp. Biochem.*, 95B(3), 545-50 (English) 1990. CODEN: CBPBB8. ISSN: 0305-0491.
- L36 ANSWER 62 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1990:588492 Document No. 113:188492 In vitro synthesis and secretion of lipophorin by the fat body of nondiapauses and prediapauses larvae of the southwestern corn borer, *Diatraea grandiosella*. Shelby, Kent S.; Chippendale, G. Michael (Dep. Entomol., Univ. Missouri, Columbia, MO, 65211, USA). *Insect Biochem.*, 20(5), 517-22 (English) 1990. CODEN: ISBCAN. ISSN: 0020-1790.
- L36 ANSWER 63 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1991:244555 Document No. 114:244555 Biochemistry of the evolution of *Triatoma infestans*. XI. Hemolymph lipophorin. Rimoldi, Omar J.; Soulages, Jose L.; Gonzalez, Maria S.; Peluffo, Raul O.; Brenner, Rodolfo R. (Inst. Invest. Bioquim. La Plata, UNLP, La Plata, 1900, Argent.). *Acta Physiol. Pharmacol. Latinoam.*, 40(2), 239-55 (English) 1990. CODEN: APPLF. ISSN: 0326-6656.
- L36 ANSWER 64 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1991:3816 Document No. 114:3816 Quantitation of apolipoproteins A-I, A-II and B in normal subjects in Jinan area. Xu, Mingyi; Hu, Weicheng; Liu, Yumei; Li, Li; Fan, Lihua (Dep. Pathophysiol., Shandong Med. Univ., Jinan, Peop. Rep. China). *Shandong Yike Daxue Xuebao*, 28(2), 17-20 (Chinese) 1990. CODEN: SYXBEE.
- L36 ANSWER 65 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1989:474071 Document No. 111:74071 A strategy for solubilizing delipidated apolipoprotein with lysophosphatidylcholine and reconstitution with phosphatidylcholine. Kawooya, John K.; Wells, Michael A.; Law, John H. (Dep. Biochem., Univ. Arizona, Tucson, AZ, 85721, USA). *Biochemistry*, 28(16), 6658-67 (English) 1989. CODEN: BICHAW. ISSN: 0006-2960.
- L36 ANSWER 66 OF 124 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
1989:265373 Document No.: BA88:1455. HIGH LEVELS OF HUMAN APOLIPOPROTEIN A-I IN TRANSGENIC MICE RESULT IN INCREASED PLASMA LEVELS OF SMALL HIGH DENSITY LIPOPROTEIN HDL PARTICLES COMPARABLE TO HUMAN HDL-3. WALSH A; ITO Y; BRESLOW J L. ROCKEFELLER UNIV., 1230 YORK AVE., NEW YORK, N.Y. 10021.. *J BIOL CHEM*, (1989) 264 (11), 6488-6494. CODEN: JBCHA3. ISSN: 0021-9258. Language: English.
- L36 ANSWER 67 OF 124 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
89220147 EMBASE Document No.: 1989220147. The apolipoprotein A-I gene is actively expressed in the rapidly myelinating avian peripheral nerve. LeBlanc A.C.; Foldvari M.; Spencer D.F.; Breckenridge W.C.; Fenwick R.G.; Williams D.L.; Mezei C.. Department of Neurology, Mayo Clinic, Rochester, MN 55905, United States. *Journal of Cell Biology* 109/3 (1245-1256) 1989. ISSN: 0021-9525. CODEN: JCLBA3. Pub. Country: United States. Language: English. Summary Language: English.



L36 ANSWER 68 OF 124 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
1990:81938 Document No.: BR38:37528. HERITABILITY OF **APO-I**

**APO B LIPOPROTEIN A AND LOW DENSITY LIPOPROTEIN**  
SUBCLASSES. LAMON-FAVA S; JIMENEZ D; CHRISTIAN J C; REED T; FABSITZ R R;  
ORDOVAS J M; WILSON P W F; SCHAEFER E J. USDA HUMAN NUTR. RES. CENTER  
AGING, TUFTS UNIV., BOSTON, MASS.. 62ND SCIENTIFIC SESSIONS OF THE  
AMERICAN HEART ASSOCIATION, NEW ORLEANS, LOUISIANA, USA, NOVEMBER 13-16,  
1989. CIRCULATION. (1989) 80 (4 SUPPL 2), II408. CODEN: CIRCAZ. ISSN:  
0009-7322. Language: English.

L36 ANSWER 69 OF 124 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
DUPLICATE 6

1989:160931 Document No.: BA87:83032. CHANGES OF PROPERTIES IN LIPOPHORIN OF  
THE SILKWORM BOMBYX-MORI WITH ONTOGENY. MIURA K; SHIMIZU I. RES. SECT.  
ENVIRON. BIOL., LAB. PLANT ECOL. STUD., FAC. SCI., KYOTO UNIV., KYOTO 606,  
JPN.. COMP BIOCHEM PHYSIOL B COMP BIOCHEM, (1989) 92 (1), 197-204. CODEN:  
CBPBB8. ISSN: 0305-0491. Language: English.

L36 ANSWER 70 OF 124 CAPLUS COPYRIGHT 2002 ACS

1990:32203 Document No. 112:32203 Binding of juvenile hormone III to  
lipophorin from the American cockroach *Periplaneta americana*. De Kort,  
Stan; Koopmanschap, Bertha (Dep. Entomol., Agric. Univ., Wageningen, 6700  
EH, Neth.). Arch. Insect Biochem. Physiol., 11(3), 159-72 (English) 1989.  
CODEN: AIBPEA. ISSN: 0739-4462.

L36 ANSWER 71 OF 124 CAPLUS COPYRIGHT 2002 ACS

1989:227399 Document No. 110:227399 Lipophorin from *Rhodnius prolixus*:  
purification and partial characterization. Gondim, Katia C.; Oliveira,  
Pedro L.; Coelho, Heloisa S. L.; Masuda, Hatisaburo (Cent. Cienc. Saude,  
Univ. Fed. Rio de Janeiro, Rio de Janeiro, 21 910, Brazil). Insect  
Biochem., 19(2), 153-61 (English) 1989. CODEN: ISBCAN. ISSN: 0020-1790.

L36 ANSWER 72 OF 124 CAPLUS COPYRIGHT 2002 ACS

1988:124749 Document No. 108:124749 Estrogen-induced destabilization of yolk  
precursor protein mRNAs in avian liver. Gordon, David A.; Shelness,  
Gregory S.; Nicosia, Monica; Williams, David L. (Health Sci. Cent., State  
Univ. New York, Stony Brook, NY, 11794, USA). J. Biol. Chem., 263(6),  
2625-31 (English) 1988. CODEN: JBCHA3. ISSN: 0021-9258.

L36 ANSWER 73 OF 124 MEDLINE

DUPLICATE 7

89176713 Document Number: 89176713. PubMed ID: 3235913. Isolation of  
apolipoproteins from carotenoid-carrying **lipoprotein** in the  
serum of chum salmon, *Oncorhynchus keta*. Ando S; Hatano M. (Laboratory of  
Food Chemistry I, Faculty of Fisheries, Hokkaido University, Japan.)  
JOURNAL OF LIPID RESEARCH, (1988 Oct) 29 (10) 1264-71. Journal code:  
0376606. ISSN: 0022-2275. Pub. country: United States. Language: English.

L36 ANSWER 74 OF 124 CAPLUS COPYRIGHT 2002 ACS

1989:54679 Document No. 110:54679 Relationship of hemolymph juvenile  
hormone-binding protein to lipophorin in *Leucophaea maderae*. Rayne,  
Richard C.; Koeppe, John K. (Dep. Biol., Univ. North Carolina, Chapel  
Hill, NC, 27514, USA). Insect Biochem., 18(7), 667-73 (English) 1988.  
CODEN: ISBCAN. ISSN: 0020-1790.

L36 ANSWER 75 OF 124 CAPLUS COPYRIGHT 2002 ACS

1989:20648 Document No. 110:20648 Separation of lipid-free egg yolk proteins  
by high-pressure liquid chromatography using solvents containing formic  
acid. Sheumack, D. D.; Burley, R. W. (ICI-Kortec Pty Ltd., 2116,  
Australia). Anal. Biochem., 174(2), 548-51 (English) 1988. CODEN:  
ANBCA2. ISSN: 0003-2697.

L36 ANSWER 76 OF 124 CAPLUS COPYRIGHT 2002 ACS

1988:527819 Document No. 109:127819 Arterial deepvenous difference of

**lipoproteins** in skeletal muscle of patients in postoperative state: effects of medium chain triglyceride emulsion. Hailer, S.; Jauch, K. W.; Guenther, B.; Wolfram, G.; Zoellner, N.; Heberer, G. (Inst. Nutr. Sci., Tech. Univ. Munich-Weihenstephan, Freising, D-8050, Fed. Rep. Ger.). JPEN, J. Parenter. Enteral Nutr., 12(4), 377-81 (English) 1988. CODEN: JPENDU. ISSN: 0148-6071.

L36 ANSWER 77 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1989:132420 Document No. 110:132420 Adipokinetic response of a flightless grasshopper (*Barytettix psolus*): functional components, defective response. Ziegler, Rolf; Ryan, Robert O.; Arbas, Edmund A.; Law, John H. (Dep. Biochem., Univ. Arizona, Tucson, AZ, 85721, USA). Arch. Insect Biochem. Physiol., 9(4), 255-68 (English) 1988. CODEN: AIBPEA. ISSN: 0739-4462.

L36 ANSWER 78 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1988:219206 Document No. 108:219206 Isolation and fluorescence studies on a lipophorin from the weevil *Diaprepes abbreviatus*. Shapiro, Jeffrey P. (Agric. Res. Serv., U.S. Dep. Agric., Orlando, FL, USA). Arch. Insect Biochem. Physiol., 7(2), 119-31 (English) 1988. CODEN: AIBPEA. ISSN: 0739-4462.

L36 ANSWER 79 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1988:53173 Document No. 108:53173 Lipophorin conversions during flight of the death's-head hawkmoth *Acherontia atropos*. Surholt, Bernhard; Schulz, Thomas K. F.; Goldberg, Jutta; Van der Horst, Dick J.; Beenackers, Ad M. T. (Zool. Inst., Univ. Muenster, Muenster, D-4400, Fed. Rep. Ger.). Insect Biochem., 18(1), 117-26 (English) 1988. CODEN: ISBCAN. ISSN: 0020-1790.

L36 ANSWER 80 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1988:54297 Document No. 108:54297 Limited proteolysis of prophenoloxidase during activation by microbial products in insect plasma and effect of phenoloxidase on electrophoretic mobilities of plasma proteins. Ashida, Masaaki; Yoshida, Hideya (Inst. Low Temp. Sci., Hokkaido Univ., Sapporo, Japan). Insect Biochem., 18(1), 11-19 (English) 1988. CODEN: ISBCAN. ISSN: 0020-1790.

L36 ANSWER 81 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1987:593382 Document No. 107:193382 Small-angle x-ray scattering study of insect lipophorin. Katagiri, Chihiro; Sato, Mamoru; Tanaka, Nobuo (Inst. Low Temp. Sci., Hokkaido Univ., Sapporo, Japan). J. Biol. Chem., 262(33), 15857-61 (English) 1987. CODEN: JBCHA3. ISSN: 0021-9258.

L36 ANSWER 82 OF 124 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
87153468 EMBASE Document No.: 1987153468. Effect of lecithin:cholesterol acyltransferase on distribution of apolipoprotein A-IV among **lipoproteins** of human plasma. Bisgaier C.L.; Sachdev O.P.; Lee E.S.; et al.. Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY 10032, United States. Journal of Lipid Research 28/6 (693-703) 1987.  
CODEN: JLPRAW. Pub. Country: United States. Language: English.

L36 ANSWER 83 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1987:492199 Document No. 107:92199 **Lipoproteins** in the hemolymph of the tarantula, *Eurypelma californicum*. Haunerland, Norbert H.; Bowers, William S. (Dep. Entomol., Univ. Arizona, Tucson, AZ, 85721, USA). Comp. Biochem. Physiol., B: Comp. Biochem., 86B(3), 571-4 (English) 1987.  
CODEN: CBPBB8. ISSN: 0305-0491.

L36 ANSWER 84 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1987:473062 Document No. 107:73062 Asparagine-linked oligosaccharides of locust lipophorin. Nagao, Eriko; Takahashi, Noriko; Chino, Haruo (Inst.

Low Temp. Sci., Hokkaido Univ., Sapporo, Japan). Insect Biochem., 17(4), 531-8 (English) 1987. CODEN: ISBCAN. ISSN: 0020-1790.

L36 ANSWER 85 OF 124 CAPLUS COPYRIGHT 2002 ACS

1988:2293 Document No. 108:2293 Molecular characteristics of lipophorin, the juvenile hormone-binding protein in the hemolymph of the Colorado potato beetle. De Kort, C. A. D.; Koopmanschap, A. B. (Lab. Entomol., Agric. Univ., Wageningen, 6700EH, Neth.). Arch. Insect Biochem. Physiol., 5(4), 255-69 (English) 1987. CODEN: AIBPEA. ISSN: 0739-4462.

L36 ANSWER 86 OF 124 CAPLUS COPYRIGHT 2002 ACS

1988:546662 Document No. 109:146662 Adipokinetic hormone-induced lipophorin transformations during locust flight. Van der Horst, Dick J.; Van Heusden, Miranda C.; Schulz, Thomas K. F.; Beenackers, Ad M. T. (Dep. Exp. Zool., Univ. Utrecht, Utrecht, 3508 TB, Neth.). UCLA Symp. Mol. Cell. Biol., New Ser., 49(Mol. Entomol.), 247-56 (English) 1987. CODEN: USMBD6. ISSN: 0735-9543.

L36 ANSWER 87 OF 124 MEDLINE

DUPLICATE 8

87200792 Document Number: 87200792. PubMed ID: 3573997. Studies of **lipoproteins** and fatty acids in maternal and cord blood of two racial groups in Trinidad. Taylor G O; Albers J J; Warnick G R; Adolphson J L; McFarlane H; Sullivan D R; West C E; Sri-Hari V; Edwards R. LIPIDS, (1987 Mar) 22 (3) 173-7. Journal code: 0060450. ISSN: 0024-4201. Pub. country: United States. Language: English.

L36 ANSWER 88 OF 124 CAPLUS COPYRIGHT 2002 ACS

1987:595283 Document No. 107:195283 Lipophorin in the larval and adult stages of *Musca domestica*. De Bianchi, Antonio G.; Capurro, Margareth de L.; Marinotti, Osvaldo (Inst. Quim., Univ. Sao Paulo, Sao Paulo, 01498, Brazil). Arch. Insect Biochem. Physiol., 6(1), 39-48 (English) 1987. CODEN: AIBPEA. ISSN: 0739-4462.

L36 ANSWER 89 OF 124 CAPLUS COPYRIGHT 2002 ACS

1986:569211 Document No. 105:169211 Lipophorin from the grasshopper, *Gastrimargus africanus*. Isolation and properties of apolipophorin III. Haunerland, Norbert H.; Ryan, Robert O.; Law, John H.; Bowers, William S. (Dep. Entomol., Univ. Arizona, Tucson, AZ, 85721, USA). Insect Biochem., 16(5), 797-802 (English) 1986. CODEN: ISBCAN. ISSN: 0020-1790.

L36 ANSWER 90 OF 124 CAPLUS COPYRIGHT 2002 ACS

1987:81857 Document No. 106:81857 Isolation and characterization of lipophorin from the hemolymph of diapausing larvae of the southwestern corn borer, *Diatraea grandiosella*. Dillwith, J. W.; Lenz, C. J.; Chippendale, G. M. (Dep. Entomol., Univ. Missouri, Columbia, MO, 65211, USA). J. Comp. Physiol., B, 156(6), 783-9 (English) 1986. CODEN: JPBPD L.

L36 ANSWER 91 OF 124 CAPLUS COPYRIGHT 2002 ACS

1987:28989 Document No. 106:28989 Major hemolymph proteins from larvae of the black swallowtail butterfly, *Papilio polyxenes*. Ryan, Robert O.; Wang, Xiao Yu; Willott, Elizabeth; Law, John H. (Dep. Biochem., Univ. Arizona, Tucson, AZ, 85721, USA). Arch. Insect Biochem. Physiol., 3(6), 539-50 (English) 1986. CODEN: AIBPEA. ISSN: 0739-4462.

L36 ANSWER 92 OF 124 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.

86221981 EMBASE Document No.: 1986221981. The basic apolipoprotein A-I in the patients with familial lecithin:cholesterol acyltransferase deficiency. Teramoto T.; Kato H.; Hashimoto Y.; et al.. First Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Bunkyo-ku, Tokyo 113, Japan. Scandinavian Journal of Clinical and Laboratory Investigation 46/4 (297-305) 1986. CODEN: SJCLAY. Pub. Country: Norway. Language: English.

L36 ANSWER 93 OF 124 CAPLUS COPYRIGHT 2002 ACS

1987:513210 Document No. 107:113210 Apolipoproteins in buffalo: preliminary studies. Mondola, P.; Santangelo, F.; Santillo, M.; Belfiore, A.; Bavaro, P.; Avallone, L.; Pizzuti, G. P. (Univ. Studi Napoli, Naples, Italy). *Rass. Med. Sper.*, 33(9-10), 283-92 (Italian) 1986. CODEN: RMSPAY. ISSN: 0033-9555.

L36 ANSWER 94 OF 124 MEDLINE

87096782 Document Number: 87096782. PubMed ID: 3799361. Effect of diabetes mellitus and end-stage renal disease on HDL metabolism. Tan M H. *ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY*, (1986) 201 51-9. Journal code: 0121103. ISSN: 0065-2598. Pub. country: United States. Language: English.

L36 ANSWER 95 OF 124 CAPLUS COPYRIGHT 2002 ACS

1985:74351 Document No. 102:74351 Identification of membrane-embedded domains of lipophilin from human myelin. Kahan, Ileana; Moscarello, Mario A. (Res. Inst., Hosp. Sick Child., Toronto, ON, M5G 1X8, Can.). *Biochemistry*, 24(2), 538-44 (English) 1985. CODEN: BICHAW. ISSN: 0006-2960.

L36 ANSWER 96 OF 124 CAPLUS COPYRIGHT 2002 ACS

1985:574258 Document No. 103:174258 Biochemistry of the development of *Triatoma infestans* (Vinchuca). VIII. Preliminary study of hemolymph apolipoproteins of adult males. Fichera, Laura E.; Brenner, Rodolfo R. (Inst. Invest. Bioquim., Fac. Cienc. Med., La Plata, 1900, Argent.). *Acta Physiol. Pharmacol. Latinoam.*, 35(3), 319-25 (Spanish) 1985. CODEN: APPLF.

L36 ANSWER 97 OF 124 CAPLUS COPYRIGHT 2002 ACS

1985:91625 Document No. 102:91625 Isolation of high density **lipoproteins** from rat intestinal epithelial cells. Magun, Arthur M.; Brasitus, Thomas A.; Glickman, Robert M. (Coll. Physicians Surg., Columbia Univ., New York, NY, 10032, USA). *J. Clin. Invest.*, 75(1), 209-18 (English) 1985. CODEN: JCINAO. ISSN: 0021-9738.

L36 ANSWER 98 OF 124 CAPLUS COPYRIGHT 2002 ACS

1985:108402 Document No. 102:108402 Structure of apoproteins in insect lipophorin. Kashiwazaki, Yasuo; Ikai, Atsushi (Fac. Sci., Univ. Tokyo, Tokyo, Japan). *Arch. Biochem. Biophys.*, 237(1), 160-9 (English) 1985. CODEN: ABBIA4. ISSN: 0003-9861.

L36 ANSWER 99 OF 124 CAPLUS COPYRIGHT 2002 ACS

1984:152724 Document No. 100:152724 Structural studies on lipophorin, an insect **lipoprotein**. Shapiro, Jeffrey P.; Keim, Pamela S.; Law, John H. (Dep. Biochem., Univ. Arizona, Tucson, AZ, 85721, USA). *J. Biol. Chem.*, 259(6), 3680-5 (English) 1984. CODEN: JBCHA3. ISSN: 0021-9258.

L36 ANSWER 100 OF 124 CAPLUS COPYRIGHT 2002 ACS

1984:588413 Document No. 101:188413 Chemical and immunological properties of lipophorins from seven insect orders. Ryan, Robert O.; Schmidt, Justin O.; Law, John H. (Dep. Biochem., Univ. Arizona, Tucson, AZ, 85721, USA). *Arch. Insect Biochem. Physiol.*, 1(4), 375-83 (English) 1984. CODEN: AIBPEA. ISSN: 0739-4462.

L36 ANSWER 101 OF 124 CAPLUS COPYRIGHT 2002 ACS

1984:47406 Document No. 100:47406 Structural studies of apolipoprotein A-I/phosphatidylcholine recombinants by high-field proton NMR, nondenaturing gradient gel electrophoresis, and electron microscopy. Brouillette, Christie G.; Jones, James L.; Ng, Thien C.; Kercret, Henri; Chung, B. Hong; Segrest, Jere P. (Birmingham Med. Cent., Univ. Alabama, Birmingham, AL, 35294, USA). *Biochemistry*, 23(2), 359-67 (English) 1984. CODEN: BICHAW. ISSN: 0006-2960.

- L36 ANSWER 102 OF 124 MEDLINE DUPLICATE 9  
 85144010 Document Number: 85144010. PubMed ID: 6528523. [Comparative characteristics of plasma **lipoproteins** and mesenteric lymph in the rabbit: spectrum and chemical properties]. Sravnitel'naia kharakteristika lipoproteidov plazmy krovi i mezenerial'noi limfy krolika: spektr i khimicheskii sostav. Denisenko A D; Lozovskii V T; Bergmann S; Iaros V; Klimov A N. VOPROSY MEDITSINSKOI KHIMII, (1984 Sep-Oct) 30 (5) 65-72. Journal code: 0416601. ISSN: 0042-8809. Pub. country: USSR. Language: Russian.
- L36 ANSWER 103 OF 124 CAPLUS COPYRIGHT 2002 ACS  
 1983:175160 Document No. 98:175160 Human plasma **lipoprotein** [a]. Structural properties. Gaubatz, John W.; Heideman, Carol; Gotto, Antonio M., Jr.; Morrisett, Joel D.; Dahlen, Gosta H. (Dep. Med., Methodist Hosp., Houston, TX, 77030, USA). J. Biol. Chem., 258(7), 4582-9 (English) 1983. CODEN: JBCHA3. ISSN: 0021-9258.
- L36 ANSWER 104 OF 124 CAPLUS COPYRIGHT 2002 ACS  
 1983:418191 Document No. 99:18191 Intracellular and extracellular processing of human apolipoprotein A-I: secreted apolipoprotein A-I isoprotein 2 is a propeptide. Zannis, V. I.; Karathanasis, S. K.; Keutmann, H. T.; Goldberger, G.; Breslow, J. L. (Med. Cent., Child. Hosp., Boston, MA, 02115, USA). Proc. Natl. Acad. Sci. U. S. A., 80(9), 2574-8 (English) 1983. CODEN: PNASA6. ISSN: 0027-8424.
- L36 ANSWER 105 OF 124 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
 82211077 EMBASE Document No.: 1982211077. Abnormal apoprotein A-I isoprotein composition in patients with Tangier disease. Zannis V.I.; Lees A.M.; Lees R.S.; Breslow L.. Child. Hosp. Med. Cent., Boston, MA 02115, United States. Journal of Biological Chemistry 257/9 (4978-4986) 1982. CODEN: JBCHA3. Pub. Country: United States. Language: English.
- L36 ANSWER 106 OF 124 CAPLUS COPYRIGHT 2002 ACS  
 1983:69579 Document No. 98:69579 Human apolipoprotein A-I and A-II metabolism. Schaefer, Ernst J.; Zech, Loren A.; Jenkins, Leslie L.; Bronzert, Thomas J.; Rubalcaba, Elizabeth A.; Lindgren, Frank T.; Aamodt, Roger L.; Brewer, H. Bryan, Jr. (Mol. Dis. Branch, Natl. Heart, Lung, Blood Inst., Bethesda, MD, 20205, USA). J. Lipid Res., 23(6), 850-62 (English) 1982. CODEN: JLPRAW. ISSN: 0022-2275.
- L36 ANSWER 107 OF 124 CAPLUS COPYRIGHT 2002 ACS  
 1982:471290 Document No. 97:71290 Characterization and quantitation of apolipoproteins A-I and E of normal and cholesterol-fed guinea pigs. Guo, Luke S. S.; Hamilton, Robert L.; Kane, John P.; Fielding, Christopher J.; Chen, G. Chi (Cardiovasc. Res. Inst., Univ. California, San Francisco, CA, 94143, USA). J. Lipid Res., 23(4), 531-42 (English) 1982. CODEN: JLPRAW. ISSN: 0022-2275.
- L36 ANSWER 108 OF 124 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
 1983:209166 Document No.: BA75:59166. SOYBEAN PROTEIN INDEPENDENTLY LOWERS PLASMA CHOLESTEROL LEVELS IN PRIMARY HYPER CHOLESTEROLEMIA. GOLDBERG A P; LIM A; KOLAR J B; GRUNDHAUSER J J; STEINKE F H; SCHONFELD G. WASHINGTON UNIV. SCH. OF MED., LIPID RES. CENTER-BOX 8046, 4566 SCOTT AVE., ST. LOUIS, MO 63110, USA.. ATHEROSCLEROSIS, (1982) 43 (2-3), 355-368. CODEN: ATHSBL. ISSN: 0021-9150. Language: English.
- L36 ANSWER 109 OF 124 CAPLUS COPYRIGHT 2002 ACS  
 1982:469604 Document No. 97:69604 Two low-molecular-weight apoproteins (apovitellenins I and II) from a **lipoprotein** of goose's egg yolk: a comparison with related species. Inglis, A. S.; Strike, P. M.; Burley, R. W. (Div. Protein Chem., CSIRO, Parkville, 3052, Australia). Aust. J. Biol. Sci., 35(3), 263-9 (English) 1982. CODEN: AJBSAM. ISSN:

0004-9417.

- L36 ANSWER 110 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1981:512504 Document No. 95:112504 The effects of subfractions of high density **lipoprotein** on cholesterol efflux from cultured fibroblasts. Regulation of low density **lipoprotein** receptor activity. Oram, John F.; Albers, John J.; Cheung, Marian C.; Bierman, Edwin L. (Sch. Med., Univ. Washington, Seattle, WA, 98195, USA). J. Biol. Chem., 256(16), 8348-56 (English) 1981. CODEN: JBCHA3. ISSN: 0021-9258.
- L36 ANSWER 111 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1982:118445 Document No. 96:118445 Radioimmunological determination of apolipoproteins AI and AII. Perrot, L.; Berthezene, F. (Hop. Antiquaille, INSERM, Lyon, F 69321, Fr.). Lyon Med., 246(20), 441-5 (French) 1981. CODEN: LYMEAN. ISSN: 0024-7790.
- L36 ANSWER 112 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1981:545564 Document No. 95:145564 Comparison of the nucleotide sequence of cloned DNA coding for an apolipoprotein (apoVLDL-II) from avian blood and the amino acid sequence of an egg-yolk protein (apovitellenin I): equivalence of the two sequences. Dugaiczky, A.; Inglis, A. S.; Strike, P. M.; Burley, R. W.; Beattie, W. G.; Chan, L. (Dep. Cell Biol., Baylor Coll. Med., Houston, TX, 77030, USA). Gene, 14(3), 175-82 (English) 1981. CODEN: GENED6. ISSN: 0378-1119.
- L36 ANSWER 113 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1982:48179 Document No. 96:48179 Degradation of the apoprotein A-I polypeptide chain of human high density **lipoprotein** by human plasmin. Lijnen, H. R.; Collen, D. (Cent. Thrombosis Vasc. Res., Univ. Leuven, Louvain, Belg.). Thromb. Res., 24(1-2), 151-6 (English) 1981. CODEN: THBRAA. ISSN: 0049-3848.
- L36 ANSWER 114 OF 124 MEDLINE  
80109741 Document Number: 80109741. PubMed ID: 7352991. Mechanism of action of milk **lipoprotein** lipase at substrate interfaces: effects of apolipoproteins. Jackson R L; Pattus F; de Haas G. BIOCHEMISTRY, (1980 Jan 22) 19 (2) 373-8. Journal code: 0370623. ISSN: 0006-2960. Pub. country: United States. Language: English.
- L36 ANSWER 115 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1980:616923 Document No. 93:216923 Physical, chemical, and immunochemical studies of apolipoprotein A-I from pigeon plasma high density **lipoproteins**. Mao, Simon J. T.; Downing, Michael R.; Kottke, Bruce A. (Div. Cardiovasc. Dis., Mayo Clin. Found., Rochester, MN, 55901, USA). Biochim. Biophys. Acta, 620(1), 100-10 (English) 1980. CODEN: BBACAQ. ISSN: 0006-3002.
- L36 ANSWER 116 OF 124 CAPLUS COPYRIGHT 2002 ACS  
1979:570199 Document No. 91:170199 High-density **lipoprotein** recombinants: evidence for a bicycle tire micelle structure obtained by neutron scattering and electron microscopy. Wlodawer, Alexander; Segrest, Jere P.; Chung, Byung H.; Chiovetti, Robert, Jr.; Weinstein, John N. (Natl. Meas. Lab., Natl. Bur. Stand., Washington, DC, 20234, USA). FEBS Lett., 104(2), 231-5 (English) 1979. CODEN: FEBLAL. ISSN: 0014-5793.
- L36 ANSWER 117 OF 124 SCISEARCH COPYRIGHT 2002 ISI (R)  
78:247399 The Genuine Article (R) Number: EZ137. **LIPOPROTEIN** SECRETION AND **APO-I** SYNTHESIS BY CULTURED HUMAN INTESTINAL-MUCOSA. RACHMILEWITZ D (Reprint); FAINARU M; EISENBERG S. HADASSAH UNIV HOSP & MED SCH, DEPT MED B, DIV GASTROENTEROL, JERUSALEM, ISRAEL. GASTROENTEROLOGY (1978) Vol. 74, No. 5, pp. 1081. Pub. country: ISRAEL. Language: ENGLISH.

L36 ANSWER 118 OF 124 CAPLUS COPYRIGHT 2002 ACS  
 1979:84753 Document No. 90:84753 Plasma apolipoprotein A-I and A-II levels  
 in hyperlipidemia. Schonfeld, Gustav; Bailey, Alberta; Steelman, Robert  
 (Lipid Res. Cent., Washington Univ. Sch. Med., St. Louis, Mo., USA).  
 Lipids, 13(12), 951-9 (English) 1978. CODEN: LPDSAP. ISSN: 0024-4201.

L36 ANSWER 119 OF 124 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.  
 79004467 EMBASE Document No.: 1979004467. The heterogeneity of rat high  
 density **lipoproteins**. Quarfordt S.H.; Jain R.S.; Jakoi L.; et  
 al.. Div. Gastroenterol., Dept. Med., Duke Univ. Med. Cent., Durham, N.C.  
 27710, United States. Biochemical and Biophysical Research Communications  
 83/3 (786-793) 1978.  
 CODEN: BBRCA. Pub. Country: United States. Language: English.

L36 ANSWER 120 OF 124 CAPLUS COPYRIGHT 2002 ACS  
 1976:415726 Document No. 85:15726 The amino- and carboxyl-terminal sequences  
 of canine apolipoprotein A-I. Nakai, Tsuguhiko; Whayne, Thomas F.; Tang,  
 Jordan (Lab. Protein Stud., Oklahoma Med. Res. Found., Oklahoma City,  
 Okla., USA). FEBS Lett., 64(2), 409-11 (English) 1976. CODEN: FEBLAL.

L36 ANSWER 121 OF 124 CAPLUS COPYRIGHT 2002 ACS  
 1975:475649 Document No. 83:75649 Chemistry of egg yolk. Burley, R. W.  
 (Div. Food Res., CSIRO, North Ryde, Aust.). CSIRO Food Res. Q., 35(1),  
 1-5 (English) 1975. CODEN: CFRQAM.

L36 ANSWER 122 OF 124 CAPLUS COPYRIGHT 2002 ACS  
 1974:423211 Document No. 81:23211 Ecological implications of hemolymph  
 protein patterns in some amphipod and isopod species. Alikhan, M. A.;  
 Jazdzewski, K.; Gondko, R. (Dep. Physiol. Chem., State Univ. Gent., Ghent,  
 Belg.). Curr. Sci., 43(5), 136-9 (English) 1974. CODEN: CUSCAM.

L36 ANSWER 123 OF 124 CAPLUS COPYRIGHT 2002 ACS  
 1973:462777 Document No. 79:62777 Heterogeneity of the apolipoprotein A1  
 from the HDL (high-density **lipoprotein**) fraction of human serum.  
 Ayrault-Jarrier, M.; Pastier, D.; Glangeaud, M. C.; Polonovski, J. (Lab.  
 Biochim., Fac. Med. Saint-Antoine, Paris, Fr.). Ann. Biol. Clin. (Paris),  
 31(2), 73-5 (French) 1973. CODEN: ABCLAI.

L36 ANSWER 124 OF 124 CAPLUS COPYRIGHT 2002 ACS  
 1970:410672 Document No. 73:10672 Effect of reduction and carboxymethylation  
 on the circular dichroic spectra of two polypeptide classes of serum high  
 density **lipoprotein**. Scanu, Angelo (Pritzker Sch. of Med.,  
 Univ. of Chicago, Chicago, Ill., USA). Biochim. Biophys. Acta, 200(3),  
 570-2 (English) 1970. CODEN: BBACAQ.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	379.94	380.15
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL

CA SUBSCRIBER PRICE

ENTRY  
-23.54

SESSION  
-23.54

STN INTERNATIONAL LOGOFF AT 19:20:58 ON 07 OCT 2002